Document:

Exhibit
10.44

 

PUBLIC
HEALTH SERVICE

 

COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

This
Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public
Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health
(“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration
(“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).

 

This
Cover Page identifies the Parties to this CRADA:

 

The
U.S. Department of Health and Human Services, as represented by

National Cancer Institute

an
Institute or Center (hereinafter referred to as the “IC”) of the

NIH

 

and

 

BriaCell
Therapeutics Corp. 

hereinafter referred to as the “Collaborator”,

having
offices at 820 Heinz Avenue, Berkley, California 94710, 

created and operating under the laws of Delaware.

 

    	PHS CRADA
Page 1 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

Article
1. Introduction

 

This
CRADA between IC and Collaborator will be effective when signed by the Parties, which are identified on both the Cover Page and
the Signature Page. The official contacts for the Parties are identified on the Contacts Information Page. Publicly available
information regarding this CRADA appears on the Summary Page. The research and development activities that will be undertaken
by IC and Collaborator in the course of this CRADA are detailed in the Research Plan, attached as Appendix A. The staffing, funding,
and materials contributions of the Parties are set forth in Appendix B.

 

Article
2. Definitions

 

The
terms listed in this Article will carry the meanings indicated throughout the CRADA. To the extent a definition of a term as provided
in this Article is inconsistent with a corresponding definition in the applicable sections of either the United States Code (U.S.C.)
or the Code of Federal Regulations (C.F.R.), the definition in the U.S.C. or C.F.R. will control.

 

		2.1	“Affiliate”
                                         means any corporation or other business entity controlled by, controlling, or under common
                                         control with Collaborator at any time during the term of the CRADA. For this purpose,
                                         “control” means direct or indirect beneficial ownership of at least fifty
                                         percent (50%) of the voting stock or at least fifty percent (50%) interest in the income
                                         of the corporation or other business entity.

 

		2.2	“Background
                                         Invention” means an Invention conceived and first actually reduced to practice
                                         before the Effective Date.

 

		2.3	“Collaborator
                                         Materials” means all tangible materials not first produced in the performance
                                         of this CRADA that are owned or controlled by Collaborator and used in the performance
                                         of the Research Plan.

 

		2.4	“Confidential
                                         Information” means confidential scientific, business, or financial information
                                         provided that the information does not include:

 

		(a)	information
                                         that is publicly known or that is available from public sources;

		(b)	information
                                         that has been made available by its owner to others without a confidentiality obligation;

		(c)	information
                                         that is already known by the receiving Party, or information that is independently created
                                         or compiled by the receiving Party without reference to or use of the provided information;
                                         or

		(d)	information
                                         that relates to potential hazards or cautionary warnings associated with the production,
                                         handling, or use of the subject matter of the Research Plan.

 

    	PHS CRADA
Page 2 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

		2.5	“Cooperative
                                         Research and Development Agreement” or “CRADA” means this
                                         Agreement, entered into pursuant to the Federal Technology Transfer Act of 1986, as amended
                                         (15 U.S.C. §§ 3710a et seq.), and Executive Order 12591 of April 10,
                                         1987.

 

		2.6	“CRADA
                                         Data” means all recorded information first produced in the performance of the
                                         Research Plan.

 

		2.7	“CRADA
                                         Materials” means all tangible materials first produced in the performance of
                                         the Research Plan other than CRADA Data.

 

		2.8	“CRADA
                                         Subject Invention” means any Invention of either or both Parties, conceived
                                         or first actually reduced to practice in the performance of the Research Plan.

 

		2.9	“Effective
                                         Date” means the date of the last signature of the Parties executing this Agreement.

 

		2.10	“Government”
                                         means the Government of the United States of America.

 

		2.11	“IC
                                         Materials” means all tangible materials not first produced in the performance
                                         of this CRADA that are owned or controlled by IC and used in the performance of the Research
                                         Plan.

 

		2.12	“Invention”
                                         means any invention or discovery that is or may be patentable or otherwise protected
                                         under Title 35 of the United States Code, or any novel variety of plant which is or may
                                         be protectable under the Plant Variety Protection Act, 7 U.S.C. §§ 2321 et
                                         seq.

 

		2.13	“Patent
                                         Application” means an application for patent protection for a CRADA Subject
                                         Invention with the United States Patent and Trademark Office (“U.S.P.T.O.”)
                                         or the corresponding patent-issuing authority of another nation.

 

		2.14	“Patent”
                                         means any issued United States patent, any international counterpart(s), and any corresponding
                                         grant(s) by a non-U.S. government in place of a patent.

 

		2.15	“Principal
                                         Investigator(s)” or “PI(s)” means the person(s) designated
                                         by the Parties who will be responsible for the scientific and technical conduct of the
                                         Research Plan.

 

		2.16	“Research
                                         Plan” means the statement in Appendix A of the respective research and development
                                         commitments of the Parties.

 

    	PHS CRADA
Page 3 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

Article
3. Cooperative Research and Development

 

		3.1	Performance
                                         of Research and Development. The research and development activities to be carried
                                         out under this CRADA will be performed solely by the Parties identified on the Cover
                                         Page unless specifically stated elsewhere in this Agreement. The PIs will be responsible
                                         for the scientific and technical conduct of this project on behalf of their employers.
                                         Any Collaborator employees who will work at IC facilities will be required to sign an
                                         agreement appropriately modified in view of the terms of this CRADA.

 

		3.2	Research
                                         Plan. The Parties recognize that the Research Plan describes the collaborative research
                                         and development activities they will undertake and that interim research goals set forth
                                         in the Research Plan are good faith guidelines. Should events occur that require modification
                                         of these goals, then by mutual agreement the Parties can modify them through an amendment,
                                         according to Paragraph 13.6.

 

		3.3	Use
                                         and Disposition of Collaborator Materials and IC Materials. The Parties agree to
                                         use Collaborator Materials and IC Materials only in accordance with the Research Plan,
                                         not to transfer these materials to third parties except in accordance with the Research
                                         Plan or as approved by the owning or providing Party, and, upon expiration or termination
                                         of the CRADA, to dispose of these materials as directed by the owning or providing Party.

 

		3.4	Third-Party
                                         Rights in Collaborator’s CRADA Subject Inventions. If Collaborator has received
                                         (or will receive) support of any kind from a third party in exchange for rights in any
                                         of Collaborator’s CRADA Subject Inventions, Collaborator agrees to ensure that
                                         its obligations to the third party are both consistent with Articles 6 through 8 and
                                         subordinate to Article 7 of this CRADA.

 

		3.5	Disclosures
                                         to IC. Prior to execution of this CRADA, Collaborator agrees to disclose to IC all
                                         instances in which outstanding royalties are due under a PHS license agreement, and in
                                         which Collaborator had a PHS license terminated in accordance with 37 C.F.R. § 404.10.
                                         These disclosures will be treated as Confidential Information upon request by Collaborator
                                         in accordance with Paragraphs 2.4, 8.3, and 8.4.

 

Article
4. Reports

 

		4.1	Interim
                                         Research and Development Reports. The PIs should exchange information regularly,
                                         in writing. This exchange may be accomplished through meeting minutes, annual reports,
                                         detailed correspondence, and circulation of draft manuscripts.

 

		4.2	Final
                                         Research and Development Reports. The Parties will exchange final reports of their
                                         results within four (4) months after the expiration or termination of this CRADA. These
                                         reports will set forth the technical progress made; any publications arising from the
                                         research; and the existence of invention disclosures of potential CRADA Subject Inventions
                                         and/or any corresponding Patent Applications.

 

		4.3	Fiscal
                                         Reports. If Collaborator has agreed to provide funding to IC under this CRADA and
                                         upon the request of Collaborator, then concurrent with the exchange of final research
                                         and development reports according to Paragraph 4.2, IC will submit to Collaborator a
                                         statement of all costs incurred by IC for the CRADA. If the CRADA has been terminated,
                                         IC will specify any costs incurred before the date of termination for which IC has not
                                         received funds from Collaborator, as well as for all reasonable termination costs including
                                         the cost of returning Collaborator property or removal of abandoned Collaborator property,
                                         for which Collaborator will be responsible.

 

    	PHS CRADA
Page 4 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

Article
5. Staffing, Financial, and Materials Obligations

 

		5.1	IC
                                         and Collaborator Contributions. The contributions of any staff, funds, materials,
                                         and equipment by the Parties are set forth in Appendix B. The Federal Technology Transfer
                                         Act of 1986, 15 U.S.C. § 3710a(d)(1) prohibits IC from providing funds to Collaborator
                                         for any research and development activities under this CRADA.

 

		5.2	IC
                                         Staffing. No IC employees will devote 100% of their effort or time to the research
                                         and development activities under this CRADA. IC will not use funds provided by Collaborator
                                         under this CRADA for IC personnel to pay the salary of any permanent IC employee. Although
                                         personnel hired by IC using CRADA funds will focus principally on CRADA research and
                                         development activities, Collaborator acknowledges that these personnel may nonetheless
                                         make contributions to other research and development activities, and the activities will
                                         be outside the scope of this CRADA.

 

		5.3	Collaborator
                                         Funding. Collaborator acknowledges that Government funds received by Collaborator
                                         from an agency of the Department of Health and Human Services may not be used to fund
                                         IC under this CRADA. If Collaborator has agreed to provide funds to IC then the payment
                                         schedule appears in Appendix B and Collaborator will make payments according to that
                                         schedule. If Collaborator fails to make any scheduled payment, IC will not be obligated
                                         to perform any of the research and development activities specified herein or to take
                                         any other action required by this CRADA until the funds are received. IC will use these
                                         funds exclusively for the purposes of this CRADA. Each Party will maintain separate and
                                         distinct current accounts, records, and other evidence supporting its financial obligations
                                         under this CRADA and, upon written request, will provide the other Party a Fiscal Report
                                         according to Paragraph 4.3, which delineates all payments made and all obligated expenses,
                                         along with the Final Research Report described in Paragraph 4.2.

 

		5.4	Capital
                                         Equipment. Collaborator’s commitment, if any, to provide IC with capital equipment
                                         to enable the research and development activities under the Research Plan appears in
                                         Appendix B. If Collaborator transfers to IC the capital equipment or provides funds for
                                         IC to purchase it, then IC will own the equipment. If Collaborator loans capital equipment
                                         to IC for use during the CRADA, Collaborator will be responsible for paying all costs
                                         and fees associated with the transport, installation, maintenance, repair, removal, or
                                         disposal of the equipment, and IC will not be liable for any damage to the equipment.

 

    	PHS CRADA
Page 5 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

Article
6. Intellectual Property

 

		6.1	Ownership
                                         of CRADA Subject Inventions, CRADA Data, and CRADA Materials. Subject to the Government
                                         license described in Paragraph 7.5, the sharing requirements of Paragraph 8.1, and the
                                         regulatory filing requirements of Paragraph 8.2, the producing Party will retain sole
                                         ownership of and title to all CRADA Subject Inventions, all copies of CRADA Data, and
                                         all CRADA Materials produced solely by its employee(s). The Parties will own jointly
                                         all CRADA Subject Inventions invented jointly and all copies of CRADA Data and all CRADA
                                         Materials developed jointly.

 

		6.2	Reporting.
                                         The Parties will promptly report to each other in writing each CRADA Subject Invention
                                         reported by their respective personnel, and any Patent Applications filed thereon, resulting
                                         from the research and development activities conducted under this CRADA. Each Party will
                                         report all CRADA Subject Inventions to the other Party in sufficient detail to determine
                                         inventorship, which will be determined in accordance with U.S. patent law. These reports
                                         will be treated as Confidential Information in accordance with Article 8. Formal reports
                                         will be made by and to the Patenting and Licensing Offices identified on the Contacts
                                         Information Page herein.

 

		6.3	Filing
                                         of Patent Applications. Each Party will make timely decisions regarding the filing
                                         of Patent Applications on the CRADA Subject Inventions made solely by its employee(s),
                                         and will notify the other Party in advance of filing. Collaborator will have the first
                                         opportunity to file a Patent Application on joint CRADA Subject Inventions and will notify
                                         PHS of its decision within sixty (60) days of an Invention being reported or at least
                                         thirty (30) days before any patent filing deadline, whichever occurs sooner. If Collaborator
                                         fails to notify PHS of its decision within that time period or notifies PHS of its decision
                                         not to file a Patent Application, then PHS has the right to file a Patent Application
                                         on the joint CRADA Subject Invention. Neither Party will be obligated to file a Patent
                                         Application. Collaborator will place the following statement in any Patent Application
                                         it files on a CRADA Subject Invention: “This invention was created in the performance
                                         of a Cooperative Research and Development Agreement with the National Institutes of Health,
                                         an Agency of the Department of Health and Human Services. The Government of the United
                                         States has certain rights in this invention.” If either Party files a Patent Application
                                         on a joint CRADA Subject Invention, then the filing Party will include a statement within
                                         the Patent Application that clearly identifies the Parties and states that the joint
                                         CRADA Subject Invention was made under this CRADA.

 

		6.4	Patent
                                         Expenses. Unless agreed otherwise, the Party filing a Patent Application will pay
                                         all preparation and filing expenses, prosecution fees, issuance fees, post issuance fees,
                                         patent maintenance fees, annuities, interference expenses, and attorneys’ fees
                                         for that Patent Application and any resulting Patent(s). If a license to any CRADA Subject
                                         Invention is granted to Collaborator, then Collaborator will be responsible for all expenses
                                         and fees, past and future, in connection with the preparation, filing, prosecution, and
                                         maintenance of any Patent Applications and Patents claiming exclusively-licensed CRADA
                                         Subject Inventions and will be responsible for a pro-rated share, divided equally among
                                         all licensees, of those expenses and fees for non-exclusively licensed CRADA Subject
                                         Inventions. Collaborator may waive its exclusive option rights at any time, and incur
                                         no subsequent financial obligation for those Patent Application(s) or Patent(s)

 

    	PHS CRADA
Page 6 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

		6.5	Prosecution
                                         of Patent Applications. The Party filing a Patent Application will provide the non-filing
                                         Party with a copy of any official communication relating to prosecution of the Patent
                                         Application within thirty (30) days of transmission of the communication. Each Party
                                         will also provide the other Party with the power to inspect and make copies of all documents
                                         retained in the applicable Patent Application or Patent file. The Parties agree to consult
                                         with each other regarding the prosecution of Patent Applications directed to joint CRADA
                                         Subject Inventions. If Collaborator elects to file and prosecute Patent Applications
                                         on joint CRADA Subject Inventions, then Collaborator agrees to use the U.S.P.T.O. Customer
                                         Number Practice and/or grant PHS a power(s) of attorney (or equivalent) necessary to
                                         assure PHS access to its intellectual property rights in these Patent Applications. PHS
                                         and Collaborator will cooperate with each other to obtain necessary signatures on Patent
                                         Applications, assignments, or other documents.

 

Article
7. Licensing

 

		7.1	Background
                                         Inventions. Other than as specifically stated in this Article 7, nothing in this
                                         CRADA will be construed to grant any rights in one Party’s Background Invention(s)
                                         to the other Party, except to the extent necessary for the Parties to conduct the research
                                         and development activities described in the Research Plan.

 

		7.2	Collaborator’s
                                         License Option to CRADA Subject Inventions. With respect to Government rights to
                                         any CRADA Subject Invention made solely by an IC employee(s) or made jointly by an IC
                                         employee(s) and a Collaborator employee(s) for which a Patent Application was filed,
                                         PHS hereby grants to Collaborator an exclusive option to elect an exclusive or nonexclusive
                                         commercialization license. The license will be substantially in the form of the appropriate
                                         model PHS license agreement and will fairly reflect the nature of the CRADA Subject Invention,
                                         the relative contributions of the Parties to the CRADA Subject Invention and the CRADA,
                                         a plan for the development and marketing of the CRADA Subject Invention, the risks incurred
                                         by Collaborator, and the costs of subsequent research and development needed to bring
                                         the CRADA Subject Invention to the marketplace. The field of use of the license will
                                         not exceed the scope of the Research Plan.

 

		7.3	Exercise
                                         of Collaborator’s License Option. To exercise the option of Paragraph 7.2 Collaborator
                                         must submit a written notice to the PHS Patenting and Licensing Contact identified on
                                         the Contacts Information Page (and provide a copy to the IC Contact for CRADA Notices)
                                         within three (3) months after either (i) Collaborator receives written notice from PHS
                                         that the Patent Application has been filed or (ii) the date on which Collaborator files
                                         the Patent Application. The written notice exercising this option will include a completed
                                         “Application for License to Public Health Service Inventions” and will initiate
                                         a negotiation period that expires nine (9) months after the exercise of the option. If
                                         PHS has not responded in writing to the last proposal by Collaborator within this nine
                                         (9) month period, the negotiation period will be extended to expire one (1) month after
                                         PHS so responds, during which month Collaborator may accept in writing the final license
                                         proposal of PHS. In the absence of Collaborator’s exercise of the option, or upon
                                         election of a nonexclusive license, PHS will be free to license the CRADA Subject Invention
                                         to others. These time periods may be extended at the sole discretion of PHS upon good
                                         cause shown in writing by Collaborator.

 

    	PHS CRADA
Page 7 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

		7.4	Government
                                         License in IC Sole CRADA Subject Inventions and Joint CRADA Subject Inventions. Pursuant
                                         to 15 U.S.C. § 3710a(b)(1)(A), for CRADA Subject Inventions owned solely by IC or
                                         jointly by IC and Collaborator, and licensed pursuant to the option of Paragraph 7.2,
                                         Collaborator grants to the Government a nonexclusive, nontransferable, irrevocable, paid-up
                                         license to practice the CRADA Subject Invention or have the CRADA Subject Invention practiced
                                         throughout the world by or on behalf of the Government. In the exercise of this license,
                                         the Government will not publicly disclose trade secrets or commercial or financial information
                                         that is privileged or confidential within the meaning of 5 U.S.C. § 552(b)(4) or
                                         which would be considered privileged or confidential if it had been obtained from a non-federal
                                         party.

 

		7.5	Government
                                         License in Collaborator Sole CRADA Subject Inventions. Pursuant to 15 U.S.C. §
                                         3710a(b)(2), for CRADA Subject Inventions made solely by an employee of Collaborator,
                                         Collaborator grants to the Government a nonexclusive, nontransferable, irrevocable, paid-up
                                         license to practice the CRADA Subject Invention or have the CRADA Subject Invention practiced
                                         throughout the world by or on behalf of the Government for research or other Government
                                         purposes.

 

		7.6	Third
                                         Party License. Pursuant to 15 U.S.C. § 3710a(b)(1)(B), if PHS grants an exclusive
                                         license to a CRADA Subject Invention made solely by an IC employee or jointly with a
                                         Collaborator employee, the Government will retain the right to require Collaborator to
                                         grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense
                                         to use the CRADA Subject Invention in Collaborator’s licensed field of use on terms
                                         that are reasonable under the circumstances; or, if Collaborator fails to grant a license,
                                         to grant the license itself. The exercise of these rights by the Government will only
                                         be in exceptional circumstances and only if the Government determines (i) the action
                                         is necessary to meet health or safety needs that are not reasonably satisfied by Collaborator,
                                         (ii) the action is necessary to meet requirements for public use specified by federal
                                         regulations, and such requirements are not reasonably satisfied by Collaborator; or (iii)
                                         Collaborator has failed to comply with an agreement containing provisions described in
                                         15 U.S.C. § 3710a(c)(4)(B). The determination made by the Government under this
                                         Paragraph is subject to administrative appeal and judicial review under 35 U.S.C. §
                                         203(b).

 

		7.7	Third-Party
                                         Rights in IC Sole CRADA Subject Inventions. For a CRADA Subject Invention conceived
                                         prior to the Effective Date solely by an IC employee that is first actually reduced to
                                         practice after the Effective Date in the performance of the Research Plan, the option
                                         offered to Collaborator in Paragraph 7.2 may be restricted if, before the Effective Date,
                                         PHS had filed a Patent Application and has either offered or granted a license or has
                                         executed a license in the CRADA Subject Invention to a third party. Collaborator nonetheless
                                         retains the right to apply for a license to any such CRADA Subject Invention in accordance
                                         with the terms and procedures of 35 U.S.C. § 209 and 37 C.F.R. Part 404.

 

    	PHS CRADA
Page 8 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

Article
8. Rights of Access and Publication

 

		8.1	Right
                                         of Access to CRADA Data and CRADA Materials. IC and Collaborator agree to exchange
                                         all CRADA Data and to share all CRADA Materials. If the CRADA is terminated, both Parties
                                         agree to provide CRADA Materials in quantities needed to complete the Research Plan.
                                         Such provision will occur before the termination date of the CRADA or sooner, if required
                                         by the Research Plan.

 

		8.2	Use
                                         of CRADA Data and CRADA Materials. The Parties will be free to utilize CRADA Data
                                         and CRADA Materials internally for their own purposes, consistent with their obligations
                                         under this CRADA. The Parties may share CRADA Data or CRADA Materials with their Affiliates,
                                         agents or contractors provided the obligations of this Article 8.2 are simultaneously
                                         conveyed.

 

		(a)	CRADA
                                         Data.

 

Collaborator
and IC will use reasonable efforts to keep CRADA Data confidential until published or until corresponding Patent Applications
are filed. To the extent permitted by law, each Party will have the right to use any and all CRADA Data in and for any regulatory
filing by or on behalf of the Party.

 

		(b)	CRADA
                                         Materials.

 

Collaborator
and IC will use reasonable efforts to keep descriptions of CRADA Materials confidential until published or until corresponding
Patent Applications are filed. Collaborator acknowledges that the basic research mission of PHS includes sharing with third parties
for further research those research resources made in whole or in part with NIH funding. Consistent with this mission and the
tenets articulated in “Sharing of Biomedical Research Resources: Principles and Guidelines for Recipients of NIH Research
Grants and Contracts”, December 1999, available at http://www.ott.nih.gov/policy/research_tool.aspx, following publication
either Party may make available to third parties for further research those CRADA Materials made jointly by both PHS and Collaborator.
Notwithstanding the above, if those joint CRADA Materials are the subject of a pending Patent Application or a Patent, the Parties
may agree to restrict distribution or freely distribute them. Either Party may distribute those CRADA Materials made solely by
the other Party only upon written consent from that other Party or that other Party’s designee.

 

		8.3	Confidential
                                         Information. Each Party agrees to limit its disclosure of Confidential Information
                                         to the amount necessary to carry out the Research Plan, and will place a confidentiality
                                         notice on all such information. A Party orally disclosing Confidential Information to
                                         the other Party will summarize the disclosure in writing and provide it to the other
                                         Party within fifteen (15) days of the disclosure. Each Party receiving Confidential Information
                                         agrees to use it only for the purposes described in the Research Plan. Either Party may
                                         object to the designation of information as Confidential Information by the other Party.

 

    	PHS CRADA
Page 9 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

		8.4	Protection
                                         of Confidential Information. Confidential Information will not be disclosed, copied,
                                         reproduced or otherwise made available to any other person or entity without the consent
                                         of the owning or providing Party except as required by a court or administrative body
                                         of competent jurisdiction, or federal law or regulation. Each Party agrees to use reasonable
                                         efforts to maintain the confidentiality of Confidential Information, which will in no
                                         instance be less effort than the Party uses to protect its own Confidential Information.
                                         Each Party agrees that a Party receiving Confidential Information will not be liable
                                         for the disclosure of that portion of the Confidential Information which, after notice
                                         to and consultation with the disclosing Party, the receiving Party determines may not
                                         be lawfully withheld, provided the disclosing Party has been given a reasonable opportunity
                                         to seek a court order to enjoin disclosure.

 

		8.5	Protection
                                         of Human Subjects’ Information. The research and development activities to
                                         be conducted under this CRADA are not intended to involve human subjects or human tissues
                                         within the meaning of 45 C.F.R. Part 46 and 21 C.F.R. Part 50. Should it become necessary
                                         to utilize human subjects or human tissues, or to provide a Party with access to information
                                         about identifiable human subjects, the Parties agree to amend this CRADA in accordance
                                         with Paragraph 13.6 to ensure that the research and development activities conducted
                                         hereunder will conform to the appropriate federal laws and regulations, including but
                                         not limited to all applicable FDA regulations and HHS regulations relating to the protection
                                         of human subjects.

 

		8.6	Duration
                                         of Confidentiality Obligation. The obligation to maintain the confidentiality of
                                         Confidential Information will expire at the earlier of the date when the information
                                         is no longer Confidential Information as defined in Paragraph 2.4 or three (3) years
                                         after the expiration or termination date of this CRADA. Collaborator may request an extension
                                         to this term when necessary to protect Confidential Information relating to products
                                         not yet commercialized.

 

		8.7	Publication.
                                         The Parties are encouraged to make publicly available the results of their research and
                                         development activities. Before either Party submits a paper or abstract for publication
                                         or otherwise intends to publicly disclose information about a CRADA Subject Invention,
                                         CRADA Data or CRADA Materials, the other Party will have thirty (30) days to review the
                                         proposed publication or disclosure to assure that Confidential Information is protected.
                                         Either Party may request in writing that the proposed publication or other disclosure
                                         be delayed for up to thirty (30) additional days as necessary to file a Patent Application.

 

    	PHS CRADA
Page 10 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

Article
9. Representations and Warranties

 

		9.1	Representations
                                         of IC. IC hereby represents to Collaborator that:

 

		(a)	IC
                                         has the requisite power and authority to enter into this CRADA and to perform according
                                         to its terms, and that IC’s official signing this CRADA has authority to do so.

 

		(b)	To
                                         the best of its knowledge and belief, neither IC nor any of its personnel involved in
                                         this CRADA is presently subject to debarment or suspension by any agency of the Government
                                         which would directly affect its performance of the CRADA. Should IC or any of its personnel
                                         involved in this CRADA be debarred or suspended during the term of this CRADA, IC will
                                         notify Collaborator within thirty (30) days of receipt of final notice.

 

		9.2	Representations
                                         and Warranties of Collaborator. Collaborator hereby represents and warrants to IC
                                         that:

 

		(a)	Collaborator
                                         has the requisite power and authority to enter into this CRADA and to perform according
                                         to its terms, and that Collaborator’s official signing this CRADA has authority
                                         to do so.

 

		(b)	Neither
                                         Collaborator nor any of its personnel involved in this CRADA, including Affiliates, agents,
                                         and contractors are presently subject to debarment or suspension by any agency of the
                                         Government. Should Collaborator or any of its personnel involved in this CRADA be debarred
                                         or suspended during the term of this CRADA, Collaborator will notify IC within thirty
                                         (30) days of receipt of final notice.

 

		(c)	Subject
                                         to Paragraph 12.3, and if and to the extent Collaborator has agreed to provide funding
                                         under Appendix B, Collaborator is financially able to satisfy these obligations in a
                                         timely manner.

 

Article
10. Expiration and Termination

 

		10.1	Expiration.
                                         This CRADA will expire on the last date of the term set forth on the Summary Page. In
                                         no case will the term of this CRADA extend beyond the term indicated on the Summary Page
                                         unless it is extended in writing in accordance with Paragraph 13.6.

 

		10.2	Termination
                                         by Mutual Consent. IC and Collaborator may terminate this CRADA at any time by mutual
                                         written consent.

 

		10.3	Unilateral
                                         Termination. Either IC or Collaborator may unilaterally terminate this CRADA at any
                                         time by providing written notice at least sixty (60) days before the desired termination
                                         date. IC may, at its option, retain funds transferred to IC before unilateral termination
                                         by Collaborator for use in completing the Research Plan.

 

    	PHS CRADA
Page 11 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

		10.4	Funding
                                         for IC Personnel. If Collaborator has agreed to provide funding for IC personnel
                                         and this CRADA is mutually or unilaterally terminated by Collaborator before its expiration,
                                         then Collaborator agrees that funds for that purpose will be available to IC for a period
                                         of six (6) months after the termination date or until the expiration date of the CRADA,
                                         whichever occurs sooner. If there are insufficient funds to cover this expense, Collaborator
                                         agrees to pay the difference.

 

		10.5	New
                                         Commitments. Neither Party will incur new expenses related to this CRADA after expiration,
                                         mutual termination, or a notice of a unilateral termination and will, to the extent feasible,
                                         cancel all outstanding commitments and contracts by the termination date. Collaborator
                                         acknowledges that IC will have the authority to retain and expend any funds for up to
                                         one (1) year subsequent to the expiration or termination date to cover any unpaid costs
                                         obligated during the term of the CRADA in undertaking the research and development activities
                                         set forth in the Research Plan.

 

Article
11. Disputes

 

		11.1	Settlement.
                                         Any dispute arising under this CRADA which is not disposed of by agreement of the Principal
                                         Investigators will be submitted jointly to the signatories of this CRADA. If the signatories,
                                         or their designees, are unable to jointly resolve the dispute within thirty (30) days
                                         after notification thereof, the Assistant Secretary for Health (or his/her designee or
                                         successor) will propose a resolution. Nothing in this Paragraph will prevent any Party
                                         from pursuing any additional administrative remedies that may be available and, after
                                         exhaustion of such administrative remedies, pursuing all available judicial remedies.

 

		11.2	Continuation
                                         of Work. Pending the resolution of any dispute or claim pursuant to this Article
                                         11, the Parties agree that performance of all obligations will be pursued diligently.

 

Article
12. Liability

 

		12.1	NO
                                         WARRANTIES. EXCEPT AS SPECIFICALLY STATED IN ARTICLE 9, THE PARTIES MAKE NO EXPRESS
                                         OR IMPLIED WARRANTY AS TO ANY MATTER WHATSOEVER, INCLUDING THE CONDITIONS OF THE RESEARCH
                                         OR ANY INVENTION OR MATERIAL, WHETHER TANGIBLE OR INTANGIBLE, MADE OR DEVELOPED UNDER
                                         OR OUTSIDE THE SCOPE OF THIS CRADA, OR THE OWNERSHIP, MERCHANTABILITY, OR FITNESS FOR
                                         A PARTICULAR PURPOSE OF THE RESEARCH OR ANY INVENTION OR MATERIAL, OR THAT A TECHNOLOGY
                                         UTILIZED BY A PARTY IN THE PERFORMANCE OF THE RESEARCH PLAN DOES NOT INFRINGE ANY THIRD-PARTY
                                         PATENT RIGHTS.

 

		12.2	Indemnification
                                         and Liability. Collaborator agrees to hold the Government harmless and to indemnify
                                         the Government for all liabilities, demands, damages, expenses and losses arising out
                                         of the use by Collaborator for any purpose of the CRADA Data, CRADA Materials or CRADA
                                         Subject Inventions produced in whole or part by IC employees under this CRADA, unless
                                         due to the negligence or willful misconduct of IC, its employees, or agents. The Government
                                         has no statutory authority to indemnify Collaborator. Each Party otherwise will be liable
                                         for any claims or damages it incurs in connection with this CRADA, except that IC, as
                                         an agency of the Government, assumes liability only to the extent provided under the
                                         Federal Tort Claims Act , 28 U.S.C. Chapter 171.

 

    	PHS CRADA
Page 12 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

		12.3	Force
                                         Majeure. Neither Party will be liable for any unforeseeable event beyond its reasonable
                                         control and not caused by its own fault or negligence, which causes the Party to be unable
                                         to perform its obligations under this CRADA, and which it has been unable to overcome
                                         by the exercise of due diligence. If a force majeure event occurs, the Party unable
                                         to perform will promptly notify the other Party. It will use its best efforts to resume
                                         performance as quickly as possible and will suspend performance only for such period
                                         of time as is necessary as a result of the force majeure event.

 

Article
13. Miscellaneous

 

		13.1	Governing
                                         Law. The construction, validity, performance and effect of this CRADA will be governed
                                         by U.S. federal law, as applied by the federal courts in the District of Columbia. If
                                         any provision in this CRADA conflicts with or is inconsistent with any U.S. federal law
                                         or regulation, then the U.S. federal law or regulation will preempt that provision.

 

		13.2	Compliance
                                         with Law. IC and Collaborator agree that they will comply with, and advise their
                                         contractors and agents to comply with, all applicable statutes, Executive Orders, HHS
                                         regulations, and all FDA, CDC, and NIH policies relating to research on human subjects
                                         (45 C.F.R. Part 46, 21 C.F.R. Parts 50 and 56) and relating to the appropriate care and
                                         use of laboratory animals (7 U.S.C. §§ 2131 et seq.; 9 C.F.R. Part 1,
                                         Subchapter A). Additional information on these subjects is available from the HHS Office
                                         for Human Research Protections or from the NIH Office of Laboratory Animal Welfare. Collaborator
                                         agrees to ensure that employees, contractors, and agents of Collaborator who might have
                                         access to a “select agent or toxin” (as that term is defined in 42 C.F.R.
                                         §§ 73.4-73.5) transferred from IC is properly licensed to receive the “select
                                         agent or toxin.”

 

		13.3	Waivers.
                                         None of the provisions of this CRADA will be considered waived by any Party unless a
                                         waiver is given in writing to the other Party. The failure of a Party to insist upon
                                         strict performance of any of the terms and conditions hereof, or failure or delay to
                                         exercise any rights provided herein or by law, will not be deemed a waiver of any rights
                                         of any Party.

 

		13.4	Headings.
                                         Titles and headings of the articles and paragraphs of this CRADA are for convenient reference
                                         only, do not form a part of this CRADA, and will in no way affect its interpretation.

 

		13.5	Severability.
                                         The illegality or invalidity of any provisions of this CRADA will not impair, affect,
                                         or invalidate the other provisions of this CRADA.

 

    	PHS CRADA
Page 13 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

		13.6	Amendments.
                                         Minor modifications to the Research Plan may be made by the mutual written consent of
                                         the Principal Investigators. Substantial changes to the CRADA, extensions of the term,
                                         or any changes to Appendix C will become effective only upon a written amendment signed
                                         by the signatories to this CRADA or by their representatives duly authorized to execute
                                         an amendment. A change will be considered substantial if it directly expands the range
                                         of the potential CRADA Subject Inventions, alters the scope or field of any license option
                                         governed by Article 7, or requires a significant increase in the contribution of resources
                                         by either Party.

 

		13.7	Assignment.
                                         Neither this CRADA nor any rights or obligations of any Party hereunder shall be assigned
                                         or otherwise transferred by either Party without the prior written consent of the other
                                         Party. The Collaborator acknowledges the applicability of 41 U.S.C. § 15, the Anti
                                         Assignment Act, to this Agreement. The Parties agree that the identity of the Collaborator
                                         is material to the performance of this CRADA and that the duties under this CRADA are
                                         nondelegable.

 

		13.8	Notices.
                                         All notices pertaining to or required by this CRADA will be in writing, signed by an
                                         authorized representative of the notifying Party, and delivered by first class, registered,
                                         or certified mail, or by an express/overnight commercial delivery service, prepaid and
                                         properly addressed to the other Party at the address designated on the Contacts Information
                                         Page, or to any other address designated in writing by the other Party. Notices will
                                         be considered timely if received on or before the established deadline date or sent on
                                         or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt
                                         from a commercial carrier. Notices regarding the exercise of license options will be
                                         made pursuant to Paragraph 7.3. Either Party may change its address by notice given to
                                         the other Party in the manner set forth above.

 

		13.9	Independent
                                         Contractors. The relationship of the Parties to this CRADA is that of independent
                                         contractors and not agents of each other or joint venturers or partners. Each Party will
                                         maintain sole and exclusive control over its personnel and operations.

 

		13.10	Use
                                         of Name; Press Releases. By entering into this CRADA, the Government does not directly
                                         or indirectly endorse any product or service that is or will be provided, whether directly
                                         or indirectly related to either this CRADA or to any patent or other intellectual- property
                                         license or agreement that implements this CRADA by Collaborator, its successors, assignees,
                                         or licensees. Collaborator will not in any way state or imply that the Government or
                                         any of its organizational units or employees endorses any product or service. Each Party
                                         agrees to provide proposed press releases that reference or rely upon the work under
                                         this CRADA to the other Party for review and comment at least seven (7) days prior to
                                         publication. Either Party may disclose the Summary Page to the public without the approval
                                         of the other Party.

 

		13.11	Reasonable
                                         Consent. Whenever a Party’s consent or permission is required under this CRADA,
                                         its consent or permission will not be unreasonably withheld.

 

    	PHS CRADA
Page 14 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

		13.12	Export
                                         Controls. Collaborator agrees to comply with U.S. export law and regulations. If
                                         Collaborator has a need to transfer any CRADA Materials made in whole or in part by IC,
                                         or IC Materials, or IC’s Confidential Information, to a person located in a country
                                         other than the United States, to an Affiliate organized under the laws of a country other
                                         than the United States, or to an employee of Collaborator in the United States who is
                                         not a citizen or permanent resident of the United States, Collaborator will acquire any
                                         and all necessary export licenses and other appropriate authorizations.

 

		13.13	Entire
                                         Agreement. This CRADA constitutes the entire agreement between the Parties concerning
                                         the subject matter of this CRADA and supersedes any prior understanding or written or
                                         oral agreement, without limitation, the Confidential Disclosure Agreement executed by
                                         the Parties on May 14, 2020 (NCI CDA #15857-20). Upon execution of this CRADA, the CDA
                                         is hereby superseded and succeeded by the terms of this CRADA.

 

		13.14	Survivability.
                                         The provisions of Paragraphs 3.3, 3.4, 4.2, 4.3, 5.3, 5.4, 6.1-9.2, 10.3- 10.5, 11.1,
                                         12.1-12.3, 13.1-13.3, 13.10 and 13.14 will survive the expiration or early termination
                                         of this CRADA.

 

SIGNATURES
BEGIN ON THE NEXT PAGE.

 

    	PHS CRADA
Page 15 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

PUBLIC
HEALTH SERVICE

COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

SIGNATURE
PAGE

 

ACCEPTED
AND AGREED

 

BY
EXECUTING THIS AGREEMENT, EACH PARTY REPRESENTS THAT ALL STATEMENTS MADE HEREIN ARE TRUE, COMPLETE, AND ACCURATE TO THE BEST OF
ITS KNOWLEDGE. COLLABORATOR ACKNOWLEDGES THAT IT MAY BE SUBJECT TO CRIMINAL, CIVIL, OR ADMINISTRATIVE PENALTIES FOR KNOWINGLY
MAKING A FALSE, FICTITIOUS, OR FRAUDULENT STATEMENT OR CLAIM.

 

	FOR
    IC:	 	 
	 	 	 
	/s/
    Douglas R. Lowy, M.D.	 	10/23/20
	Signature	 	Date
	 	 	 
	Douglas
    R. Lowy, M.D.	 	 
	Deputy
    Director, NCI	 	 

 

	FOR
    COLLABORATOR:	 	 
	 	 	 
	/s/
    William V. Williams, M.D.	 	2020
    October 28
	Signature	 	Date
	 	 	 
	William
    V. Williams, M.D.	 	 
	President
    and CEO	 	 

 

    	PHS CRADA
Page 16 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

PUBLIC
HEALTH SERVICE

COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

CONTACTS
INFORMATION PAGE

 

CRADA
Notices

 

	For
                                         IC:

        Technology
        Transfer Center

        National
        Cancer Institute

        9609
        Medical Center Drive

        Bethesda,
        MD 20892-9702 MSC 9702

        Rockville,
        MD 20850-9702 (express mail)

        Tel:
        240-276-5530/Fax: 240-276-5504

        
	For
                                         Collaborator:

        William
        V. Williams, M.D.

        BriaCell
        Therapeutics Corp.

        620
        South Eagle Road

        Havertown,
        PA 19083

        Office:
        1- 888-485-6340

        Cell:
        1- 302-290-9017

        Fax:
        1- 424-245-3719

        Email:
williams@BriaCell.com

 

Patenting
and Licensing

 

	For
                                         IC:

        Same
as above.
	For
                                         Collaborator (if separate from above):

        Same
as above.

 

Finances

 

	For
    IC:	For
    Collaborator (if separate from above):
	Technology
    Transfer Manager for Finances	Same
    as above.
	NCI,
    Technology Transfer Center	 
	9609
                                         Medical Center Dr., 1E-452, MSC 9702

        Bethesda,
        MD 20892-9702
	 
	Tel:
    240-276-5510	 
	Email:
    Bonnie.Chamberlain@nih.gov	 
	EIN:
    52-0858115	 

 

Delivery
of Materials Identified in Appendix B (if any)

 

	For
                                         IC:

        Jay
        A. Berzofsky, M.D., Ph.D.

        Chief,
        NCI CCR Vaccine Branch

        Bldg.
        41—Rm D702D (MSC-5062)

        National
        Institutes of Health

        41
        Medlars Drive

        Bethesda,
        Maryland 20892-5062 USA

        Tel:
        240-760-6148

        Fax:
        240-541-4452

        Email:
        berzofsj@mail.nih.gov

        
	 

        For
        Collaborator:

        William
        V. Williams, M.D.

        BriaCell
        Therapeutics Corp.

        820
        Heinz Avenue

        Berkeley,
        CA 94710

        Office:
        1- 888-485-6340

        Cell:
        1- 302-290-9017

        Fax:
        1- 424-245-3719

        Email:
        williams@BriaCell.com

 

    	PHS CRADA
Page 17 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

PUBLIC
HEALTH SERVICE

COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

SUMMARY
PAGE

 

EITHER
PARTY MAY, WITHOUT FURTHER CONSULTATION OR PERMISSION, RELEASE THIS SUMMARY PAGE TO THE PUBLIC.

 

	TITLE
    OF CRADA:	Evaluation
    of BriaCell Therapeutics Corp.’s proprietary Bria-OTS cellular immunotherapy using dendritic cell lines as vehicles
    for cancer vaccines
	 	 
	 	 
	IC
    Component:	National
    Cancer Institute 
	IC
    Principal Investigator:	Jay
    Berzofsky, M.D., Ph.D.
	 	 
	Collaborator:	BriaCell
    Therapeutics Corp. 
	Collaborator
    Principal Investigator:	William
    V. Williams, M.D.
	 	 
	TERM
    OF CRADA:	Three
    (3) years from the Effective Date.

 

ABSTRACT
OF THE RESEARCH PLAN:

 

The
National Cancer Institute and BriaCell Therapeutics Corp. will work together to conduct preclinical studies under a Cooperative
Research and Development Agreement (CRADA) to develop and test BriaCell Therapeutic Corp.’s proprietary Bria-OTS cellular
immunotherapy as a treatment for cancer to improve and broaden applicability of this therapeutic strategy.

 

    	PHS CRADA
Page 18 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

PUBLIC
HEALTH SERVICE

COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

APPENDIX
A

 

RESEARCH
PLAN

 

GOAL
AND SCOPE OF THIS CRADA

 

The
principal goal of this CRADA is to evaluate the use of BriaCell Therapeutic Corp.’s (BriaCell) proprietary Bria-OTS cellular
immunotherapy as a treatment for cancer to improve and broaden the applicability of this therapeutic strategy. More specifically,
using BriaCell’s proprietary Bria-OTS cellular immunotherapy, the NCI Vaccine Branch (VB) and BriaCell researchers will
develop and test allogeneic, immortalized mouse and potentially human dendritic cells (DCs) that express select sets of mouse
major histocompatibility complex (MHC) or human leukocyte antigen (HLA) alleles to match tumors in mouse models or human patients,
respectively.

 

The
scope of this CRADA Research Plan, including any in vitro and in vivo testing conducted by Dr. Jay Berzofsky and
members of Dr. Berzofsky’s laboratory, is strictly limited to the development of BriaCell’s proprietary Bria-OTS cellular
immunotherapy to treat cancer.

 

INTRODUCTION

 

Although
there have been major advances in the field of cancer immunotherapy with the approval of sipuleucel-T (PROVENGE®), ipilumumab
(YERVOY®), as well as pembrolizumab (KEYTRUDA®), nivolumab (OPDIVO®), and several other immunotherapeutic agents,
a significant challenge that remains is the identification and characterization of immunologic responses that correlate with beneficial
clinical outcomes and could potentially help stratify patients into predicted responders and non-responders. The reason for the
limited success of cancer vaccines appears to be their contravention by immunosuppressive mechanisms such as cytokines, e.g.,
TGF-beta and IL-10, cell surface checkpoints, e.g., PD-1 and CTLA-4, and by cellular components, e.g., T-regulatory cells, myeloid-derived
suppressor cells and regulatory NKT cells to name a few, rather than the absolute lack of immune response to the vaccine target.

 

The
Berzofsky laboratory focuses on elucidating new fundamental principles governing T cell activation, regulation, and effector function,
and employing these to develop more effective vaccine and immunotherapy strategies for HIV, cancer, and viruses causing cancer.
They previously established that an adenovirus vaccine expressing the extracellular and transmembrane domains of HER-2 can cure
large established mammary cancers and lung metastases in mice through a mechanism that involves antibodies that inhibit HER-2
function, rather than T cells. Following the publication of these results, they made a similar recombinant adenovirus expressing
the human HER-2 domains, which is being investigated clinically in human cancer patients. The vaccine consists of autologous DCs
transduced with the Ad-HER2 vector [1].

 

    	PHS CRADA
Page 19 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

PUBLIC
HEALTH SERVICE

COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

Autologous
DC-based vaccination approaches have shown promise in clinical trials [1-5] but are, however, expensive and labor-intensive. BriaCell
researchers have developed a novel class of targeted immunotherapy for patients with metastatic or recurrent breast cancer who
have previously failed at least one line of treatment. SV-BR-1-GM is a therapeutic breast cancer cell line that expresses class
I and II HLA complex genes. They have successfully demonstrated in a Phase I/IIa clinical trial that SV-BR-1-GM is a safe therapy,
and they demonstrated its efficacy by inducing biological response and tumor shrinkage in HLA-matched breast cancer patients.
Since only an estimated 47% of the U.S. population matches one or more of the relevant class II HLA alleles expressed in the SV-BR-1-GM
cells, four discrete allogeneic cell lines each overexpressing distinct HLA alleles were designed to match over 99% of the U.S.
population based on their HLA type. These cell lines, referred to as Bria-OTSTM (off-the-shelf), represent novel therapeutics
for use in treatment regimens anticipated to be more effective, less toxic, and with greater impact on long-term survival than
current therapies.

 

Unlike
other approaches where specific molecules involved in T cell deactivation (e.g., PD-1) are targeted, often resulting in
serious immune-related side effects, Bria-OTS cellular immunotherapy uniquely targets specific patient populations based on their
immune system and tumor type (i.e., precision treatment). The company’s targeted therapeutic enlists and empowers
the patient’s immune system to attack tumors. Thus, once a patient’s HLA signature is known, the necessary Bria-OTS
cell line (or a combination of cell lines) that match at least one HLA allele of the patient can be assigned for treatment, and
treatment can begin immediately, without the need for patient-specific manufacturing. BriaCell has previously demonstrated that
tumor- directed immune responses may occur using allogeneic breast cancer cell lines with properties of antigen-presenting cells
(APCs) [6].

 

EXPERTISE
OF THE PARTIES

 

	 	●	Vaccine
    Branch, CCR, NCI: The NCI Vaccine Branch has expertise in translating novel anti-cancer vaccines it has developed, from
    the preclinical research stage to clinical investigation, in order to harness a patient’s own immune system to fight
    against cancer or chronic infections. Jay A. Berzofsky, M.D., Ph.D., Chief of the Vaccine Branch, and colleagues have
    expertise in T cell immunology and tumor immunology and translation of basic immunological research to strategies to develop
    vaccines for cancer, human immunodeficiency virus (HIV), and viruses that cause cancer. The Vaccine Branch Clinical Trials
    Team is exploring various strategies to broaden cancer treatment options with lower toxicity customized to individual
    patients.

 

    	PHS CRADA
Page 20 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

PUBLIC
HEALTH SERVICE

COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

	 	●	BriaCell
    Therapeutics Corp.: BriaCell Therapeutics Corporation (BriaCell) has experience in drug discovery and drug development
    from first in human studies through post-approval and marketing. William V. Williams, M.D., President and CEO, and Markus
    Lacher, Ph.D., Head of Research and Development, have expertise in immunology, molecular biology, clinical pharmacology, drug
    development, cellular therapies, pharmacodynamic marker development and validation. Together they have over 40 years of experience
    in these fields and over 150 scientific publications, over 30 successful Investigational New Drug (IND) applications and over
    10 successful New Drug Applications. BriaCell is an immuno-oncology focused biotechnology company developing targeted and
    safe approaches for the management of cancer. BriaCell is focused on the development of cellular immunotherapies utilizing
    cell lines that can induce potent and selective anti-cancer immune responses.
	 	 	 
	 	●	Jointly:
    The NCI Vaccine Branch and BriaCell will utilize their combined expertise to design experiments and develop reagents which
    will permit delineation of the importance of MHC matching in the efficacy of cellular immunotherapies for cancer. They will
    specifically use their expertise in tumor immunology, molecular biology and development of cellular therapies to design murine
    experiments which will illuminate the relevant immunologic pathways necessary to develop an effective immune response against
    cancer. This will lead to the development of novel human therapeutics which could be the subject of future clinical collaborations.

 

EXPERIMENTAL
PLAN

 

The
experimental details that follow are approximate and may be changed upon mutual agreement of the NCI and Collaborator. Any substantive
change to the Research Plan will be by mutual agreement and written Amendment to this CRADA.

 

Whereas
BriaCell’s approach with an irradiated, human breast cancer cell line (SV-BR-1-GM) with properties of
antigen-presenting cells (APCs) [6] has shown tumor regressions in advanced breast cancer patients with HLA match(es) to the
cell line, the approach is not optimized as SV- BR-1-GM does not show all critical features of APCs including expression of
co-stimulatory molecules such as CD80 or CD86. Therefore, the NCI and BriaCell researchers will optimize the strategy by
engineering cell lines representing bona fide DCs. This project is aimed at establishing proof-of-concept data in a mouse
model. Positive data would then serve as supporting information for an investigational drug application (IND) for a clinical
study in solid tumors.

 

    	PHS CRADA
Page 21 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

PUBLIC
HEALTH SERVICE

COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

The researchers propose to develop a mouse model of this therapeutic strategy in which a mouse DC line
is used either unmodified or modified with additional MHC alleles or other immunostimulatory molecules. This mouse DC line
can be transduced with the mouse Ad-HER2 vector or pulsed with peptides from tumor antigens of other mouse tumors. By using
mice that differ in only one class I or one class II MHC allele or all of the MHC, the researchers will examine the ability
of these DCs that are partially matched or fully allogeneic to present antigen in vitro and to induce anti-tumor
immunity in vivo in mice. The approaches developed can then be translated to the human equivalent in the
clinic.

 

The
NCI and BriaCell researchers envision two projects, of which the second is optional and may only be conducted pending the results
of the first project and if factors such as the availability of sufficient funds are in place and the mutual agreement of the
Parties.

 

In
the first project, immune activation and functional links between the MHC type of a murine DC line (DC2.4) expressing GM-CSF in
mice will be assessed. Initially, the researchers will use the DC2.4 mouse DC line from Millipore-Sigma and modify that as needed.
DC2.4 cells are immortalized murine DCs created by transducing bone marrow isolates of C57BL/6 mice with retrovirus vectors expressing
murine granulocyte-macrophage CSF (GM-CSF) and the myc and raf oncogenes. DC2.4 exhibits characteristic features
of DCs including cell morphology, the expression of DC-specific markers, and the ability to phagocytose and present exogenous
antigens on both MHC I and II molecules (from product Data Sheet).

 

	 	●	DC2.4
    cells will be engineered to express either i) MHC Class Ia, K: bm3, ii) MHC Class II, A: bm12, or iii) MHC Class Ia,
    K: bm3 and MHC Class II, A: bm12. DC2.4 cells with the bm3 and bm12 modifications as well as unmodified DC2.4 cells
    will be irradiated (to prevent in vivo replication), pulsed with antigenic peptides, then inoculated into mice with
    and without MHC matches to the cell lines. Spleens and PBMCs of inoculated animals will be harvested, splenic DCs will be
    isolated using CD11c beads, pulsed with the antigenic peptides, then used as target cells for cytotoxicity experiments using
    splenic T cells as effector cells. The Parties hypothesize that the highest level of cytotoxicity will be achieved in the
    absence of MHC mismatch (i.e., with MHC match).
	 	 	 
	 	●	To
    assess whether MHC match/mismatch between the DC2.4 vaccine cells affects therapeutic efficacy in a mouse model, C57BL/6 mice
    will be inoculated with B16 tumor cells (DC2.4 and B16 cells are syngeneic with C57BL/6 mice). Once tumors are established,
    unmodified and MHC-modified DC2.4 cells will be irradiated, pulsed with peptides representing antigens expressed in B16 cells
    (i.e., gp100), and inoculated into the tumor-bearing mice. The Parties hypothesize that the highest degree of tumor shrinkage
    will be achieved in the absence of MHC mismatch (i.e., with MHC match).

 

    	PHS CRADA
Page 22 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

PUBLIC
HEALTH SERVICE

COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

Support
of the hypotheses stated for the first project would indicate support for an IND application package. Assuming the availability
of sufficient financial resources and the mutual agreement of the Parties, the researchers will conduct a second project in which
human leukemic cell lines with features of DC lines will be HLA-engineered to match a high percentage of patients. IND-enabling
in vitro studies will be conducted.

 

DESCRIPTION
OF THE CONTRIBUTIONS AND RESPONSIBILITIES OF THE PARTIES

 

VACCINE
BRANCH (VB)/CCR/NCI

 

NCI
VB will provide:

 

	 	●	Expertise
    in mouse models of cancer and immune regulatory mechanisms in cancer, as well as cancer vaccines.
	 	●	Laboratory
    and animal facilities, reagents and other materials to carry out the experiments described.
	 	●	Use
    of NCI Core facilities including the Vaccine Branch Flow Cytometry Core.

 

COLLABORATOR

Collaborator
will provide:

 

	 	●	Expertise
    in cellular immunotherapy.
	 	●	Laboratory
    facilities, cell lines, reagents and other materials necessary for the studies.

 

COLLABORATOR
AND VB/CCR/NCI

 

Jointly
NCI VB and Collaborator will work together to conduct the planned research and publish the results of the studies conducted
under this CRADA in peer-reviewed scientific journals.

 

RELATED
NCI AND COLLABORATOR AGREEMENTS

 

NCI/BriaCell
Confidential Disclosure Agreement (NCI Reference #15857-20, effective 05/14/2020). Upon execution of this CRADA, the CDA is hereby
superseded and succeeded by the terms of this CRADA.

 

    	PHS CRADA
Page 23 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

PUBLIC
HEALTH SERVICE

COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

RELATED
INTELLECTUAL PROPERTY OF THE PARTIES

 

Collaborator
Patents and Patent Applications:

 

	PATENT/
    APPL. NO.	 	PRIORITY
    DATE	 	TITLE
	U.S.
    Patent No. 7,674,456 B2	 	14-June-2004	 	BREAST
    CANCER CELL LINES AND USES THEREOF
	PCT/US2017/
    019757	 	25-Feb-2016/

        21-Nov-2016
	 	WHOLE-CELL
    CANCER VACCINES AND METHODS FOR SELECTION THEREOF
	U.S.
    Prov. Appl. No. 63/008,456	 	9-Apr-2020	 	INDUCING
    IMMUNE RESPONSES BY TRANSFORMING CANCER CELLS INTO ANTIGEN-PRESENTING CELLS
	U.S.
    Prov. Appl. No. 63/012,840	 	20-Apr-2020	 	COMPUTER-GUIDED
    DESIGN OF ANTIBODIES INCLUDING NEUTRALIZING SARS-CoV-2 BINDING AGENTS
	U.S.
    Prov. Appl. No. 63/014,536	 	23-Apr-2020	 	METHODS
    FOR INDUCING AND ENHANCING ANTI-CANCER IMMUNE RESPONSES USING NOVEL MOLECULAR CONSTRUCTS
	U.S.
    Prov. Appl. No. 63/025,512	 	15-May-2020	 	MULTI-VALENT
    IMMUNOSTIMULATORS FOR INFECTIOUS DISEASES, AUTOIMMUNE DISEASES, ALLERGIC DISEASES AND CANCER
	U.S.
    Prov. Appl. No. 63/042,243	 	22-Jun-2020	 	MULTI-VALENT
    DECOY RECEPTORS FOR DIAGNOSIS AND/OR TREATMENT OF CORONAVIRUS INFECTION

 

NCI
Patents and Patent Applications

 

“Compositions
and Methods for Treatment of HER2-Expressing Solid Tumors.” U.S. Provisional Application #62/248,964 filed October 30, 2015.
PCT Application PCT/US2016/059680 filed October 31, 2016 (NIH Reference No. E-187-2015/0-PCT-02).

 

All
continuing (including continuation and divisional), continuation-in-part, and reissue applications, foreign counterpart applications,
and extensions of applications that are directed to the subject matter as is disclosed in the above NCI Patents and Patent Applications.

 

    	PHS CRADA
Page 24 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

PUBLIC
HEALTH SERVICE

COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

REFERENCES

 

	1.	Maeng,
    H.M. and J.A. Berzofsky, Strategies for developing and optimizing cancer vaccines. F1000Res, 2019. 8.
	2.	Wood,
    L.V., et al., TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients
    with Stage D0 prostate cancer. Oncoimmunology, 2016. 5(8): p. e1197459.
	3.	Castiello,
    L., et al., Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and
    Immunologic Response to TARP Vaccination in Prostate Cancer Patients. Clin Cancer Res, 2017. 23(13): p. 3352-3364.
	4.	Cheever,
    M.A. and C.S. Higano, PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin
    Cancer Res, 2011. 17(11): p. 3520-6.
	5.	Skachkova,
    O.V., et al., Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung
    cancer. Exp Oncol, 2013. 35(2): p. 109-13.
	6.	Lacher,
    M.D., et al., SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature
    and Directly Activates CD4(+) T Lymphocytes. Front Immunol, 2018. 9: p. 776.

 

    	PHS CRADA
Page 25 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

PUBLIC
HEALTH SERVICE

COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

APPENDIX
B

 

STAFFING,
FUNDING AND MATERIALS/EQUIPMENT CONTRIBUTIONS OF THE PARTIES

 

Staffing
Contributions

 

IC
will provide scientific staff and other support necessary to conduct the research and other activities described in the Research
Plan. IC’s scientific staff will include IC’s Principal Investigator and technical staff.

 

IC
estimates that 1.3 person-years of effort per year will be required to complete the CRADA research.

 

Collaborator
will provide scientific staff and other support necessary to conduct the research and other activities described in the Research
Plan. Collaborator’s scientific staff will include Collaborator’s Principal Investigator and technical staff.

 

Collaborator
estimates that 1.0 person-years of effort per year will be required to complete the CRADA research.

 

Funding
Contributions

 

Collaborator
agrees to provide a total of $433,400 to support this project. Collaborator will provide $394,000 over 3 years for IC to use to
acquire technical, statistical, and administrative support for the research activities, as well as to pay for supplies and travel
expenses and Collaborator will provide a one time, non-refundable payment of $39,400 for NCI CCR infrastructure costs. Except
for CCR infrastructure funds, Collaborator agrees that IC can allocate the funding between the various categories in support of
the CRADA research.

 

Funds
will be due as follows: the first installment of $169,400, including the NCI CCR infrastructure charge, will be due within ninety
(90) days of the Effective Date. Each subsequent installment of $132,000 will be due within thirty (30) days of each anniversary
of the Effective Date.

 

CRADA
PAYMENTS:

 

Collaborator
has three options for making CRADA payments. See CRADA Payment Options at http://ttc.nci.nih.gov/forms/crada.php for specific
information on making payments using each option.

 

Option
1: Collaborator sends checks to the NCI.

Option
2: Collaborator makes payments via wire transfer.

Option
3: Collaborator makes payments using www.pay.gov.

 

    	PHS CRADA
Page 26 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012

    	 

    

 

PUBLIC
HEALTH SERVICE

COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

The
NCI TTC does not use a Collaborator’s payment portal or online/electronic invoicing system. If a Collaborator has any questions
regarding NCI TTC’s use of such systems, the Collaborator’s financial contact must discuss the situation with NCI
TTC’s financial contact well in advance of any need (see the Contacts Information Page of this CRADA).

 

CRADA
TRAVEL PAYMENTS:

 

Travel
arrangements for all Government staff will be made in accordance with the Federal Travel Rules and Regulations, whether arranged
by IC and funded using either appropriated funds or CRADA funds, or arranged and funded directly by Collaborator.

 

Materials/Equipment
Contributions

 

IC
will provide to the Collaborator the following IC Materials for use under this CRADA: NONE

 

Collaborator
will provide to the IC the following Collaborator Materials and/or capital equipment for use under this CRADA:

 

Collaborator
Materials: Cell lines, reagents and other materials necessary for the studies.

 

Capital Equipment: NONE

 

If
either Party decides to provide additional Materials for use under this CRADA, those Materials will be transferred under a cover
letter that identifies them and states that they are being provided under the terms of the CRADA.

 

    	PHS CRADA
Page 27 of 27
	Agreement Ref. No. 03363
Confidential
	MODEL ADOPTED June 18, 2009
Revised August 1, 2012Exhibit 10.45

 

SUBSCRIPTION AGREEMENT FOR DEBENTURE UNITS

(For U.S. Subscribers)

 

BRIACELL THERAPEUTICS CORP. 

 

	
        HAVE YOU COMPLETED THIS SUBSCRIPTION AGREEMENT
        PROPERLY?

        The following items in this Subscription
        Agreement must be completed. (Please initial each applicable box.)

         

        

	All Subscribers
	 	 	Complete all Subscriber information in the boxes on page 2
	 
	Subscribers resident in the United States
	 	 	Schedule A and Appendix 1 and 2 thereto, indicating which category (if any) is applicable.
	 	 	 
	Subscribers that are not individuals, if applicable
	 	
         

         
	Schedule C indicating which category (if any) is applicable, together with the TSX Venture Exchange Form 4C
	 

 

	
        A completed and executed copy of this Subscription
        Agreement, including all applicable schedules, must be delivered to: 

         

        Garfinkle Biderman LLP

        1 Adelaide St E, Suite 801

        Toronto, ON M5C 1J4

        Attention: Shimmy Posen 

        Fax No: 416-869-0547

        E-mail: sposen@garfinkle.com

         

 

METHOD
OF PAYMENT

 

Provide payment
of the purchase price in Canadian dollars by delivering a certified cheque, money order or bank draft made payable to “Bennett
Jones LLP in trust for BriaCell Therapeutics Corp.” or by wire to Bennett Jones LLP in trust for BriaCell Therapeutics Corp.
at:

 

	Name & Address of Beneficiary:	
        Bennett Jones LLP, in trust

        3400 One First Canadian Place P.O. Box 130

        Toronto, ON M5X 1A4

	Name & Address of Beneficiary’s Bank:	
        Royal Bank of Canada

        20 King Street West

        Toronto, Ontario M5H 1C4

	Beneficiary’s Account Number:	1161090
	Reference:	C. Travascio and J. Lewis – File # 073530.28
	ABA/Routing Number Code:	021 000 021
	Bank ID	003
	SWIFT CODE:	ROYCCAT2

 

    	 

    	2

    

 

BRIACELL THERAPEUTICS
CORP.

SUBSCRIPTION AGREEMENT
 

	TO:	
        BRIACELL THERAPEUTICS CORP. (the
“Corporation”)

 

The
undersigned (the “Subscriber”), on its own
behalf, hereby irrevocably subscribes for and agrees to purchase from the Corporation an unsecured convertible debenture unit of
the Corporation (the “Debenture Unit”) at a purchase price of $375,000 per
Debenture Unit (the “Subscription Amount”) less the original discount of approximately
29.33%, subject to the terms and conditions set forth in the attached “Terms and Conditions of Subscription for Debenture
and Warrants” (the “Terms and Conditions”, and together with this page
and the attached schedules, the “Subscription Agreement”). 

 

	
         

        Purchase Price: $265,000

        (the “Subscription Amount”)
        (Principal Amount less the original issuance discount of approximately 29.33%)
	 	
        Account Registration Information:
Same as Subscriber Information [  ] or

	 	 	(Name)
	 	 	 
	Aggregate Principal Amount: $375,000 	 	 
		 	(Account Reference, if applicable)
	 	 	 
	 	 	 
	Subscriber Information:	 	(Address, including Postal Code) (Telephone Number)
	 	 	 
	(Name of Subscriber)	 	Additional Subscriber Information:
	 	 	 
	Account Reference (if applicable):____________________	 	1. Number and kind of securities of the Issuer held, directly or indirectly, if any:
	 	 	 

	By:		 	
	 	Authorized Signature	 	

 

	 	 	 
		 	 
	 	 	2.State
        whether Subscriber is an Insider of the Issuer:

         

            Yes
        [   ]     No [  ]

	 	 	 
	(Official Capacity
    or Title – if the Subscriber is not an individual)	 	 
	 	 	 
	 	 	 
	(Name of individual
    whose signature appears above if different than the name of the Subscriber printed above.)	 	Name of Principal
	 	 	 
	 	 	Principal’s Address
	(Subscriber’s
    Address, including Municipality and Province)	 	 
	 	 	 
	 	 	City/Town                      Province                           Postal
    Code
	 	 	 
	 	 	 
	(Telephone Number)                          
    (Email Address)	 	Principal’s Telephone
    Number -OR- E-mail Address

 

    	 

    	3

    

 

ACCEPTANCE: The Corporation hereby accepts
the subscription as set forth above on the terms and conditions contained in this Subscription this day of November, 2020.

 

	 	BRIACELL THERAPEUTICS CORP. 
	 	 	 
	 	Per:	 
	 	 	Authorized Signatory

 

    	 

    	4

    

 

TERMS
AND CONDITIONS OF SUBSCRIPTION FOR DEBENTURE AND WARRANTS

 

		1.	Subscription
                                         for the Debenture and Warrants. The Subscriber, on its own behalf, hereby tenders
                                         to the Corporation this Subscription Agreement which, upon acceptance by the Corporation,
                                         will constitute an irrevocable agreement of the Subscriber to purchase from the Corporation
                                         and, of the Corporation to issue and sell to the Subscriber the Debenture Unit, all on
                                         and subject to the terms and conditions set out in this Subscription Agreement, for the
                                         Subscription Amount, which is payable as described in Sections 4 and 5 hereto (the offer,
                                         issue and sale of the Debenture and Warrants, the “Offering”).

 

		(a)	The
                                         Debenture Unit is comprised of (i) $375,000 principal amount (“Principal Amount”)
                                         of a 5% convertible unsecured debenture of the Corporation (the “Debenture”),
                                         due on the Maturity Date (as defined herein), and such Principal Amount having a purchase
                                         price of $265,000 after being reduced by an original issuance discount equal to approximately
                                         29.33%; and (ii) 69,188 common share purchase warrants of the Corporation (“Warrants”).
                                         Each Debenture is convertible, at the option of the holder, from the period beginning
                                         on the date that is six (6) months following the Closing Date, until the repayment of
                                         the Debenture in full, into that number of common shares of the Corporation (“Common
                                         Shares”) computed on the basis of the principal amount of the Debentures divided
                                         by the conversion price of C$5.42 per Common Share (the “Conversion Price”).
                                         Each Warrant entitles the holder thereof to purchase one Common Share of the Corporation
                                         (each a “Warrant Share”) for a period of five (5) years from the Closing
                                         Date at a price of C$5.42 per Warrant Share subject to adjustment as set forth in the
                                         Warrants. Each Warrant may also be exercised by presentation and surrender of the Warrant
                                         to the Corporation with a written notice of the Subscriber’s intention to effect
                                         a cashless exercise, including a calculation of the number of Common Shares to be issued
                                         upon such exercise in accordance with the terms of the Warrant certificate (a “Cashless
                                         Exercise”). In the event of a Cashless Exercise, in lieu of paying the exercise
                                         price in cash, the holder shall surrender the Warrant for that number of Common Shares
                                         equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

A
= the volume weighted average trading price of the Common Shares on the TSX Venture Exchange or if the Common Shares are not then
listed on the TSX Venture Exchange, on such other Canadian stock exchange as may be selected by the directors of the Corporation
for such purpose or, if the Common Shares are not then listed on any Canadian stock exchange, in the over-the-counter market,
for the one (1) day period ending on the trading day immediately preceding the date on which Warrantholder elects to exercise
this Warrant Certificate by means of a “cashless exercise,” as set forth in the applicable subscription form substantially
in the form attached as Schedule A;

 

B
= the Exercise Price of this Warrant Certificate, as adjusted hereunder; and

 

X
= the number of Common Shares that would be issuable upon exercise of this Warrant Certificate in accordance with the terms of
this Warrant Certificate if such exercise were by means of a cash exercise rather than a cashless exercise.

 

Upon
payment of the Subscription Amount, the Subscriber will receive a Debenture Unit comprised of (i) the Debenture and (ii) 69,188
Warrants. The description of the Debenture Unit, Debentures and the Warrants in this Subscription Agreement is a summary only
and is subject to the detailed provisions of the certificates representing the Debentures and the Warrants.

 

    	 

    	5

    

 

		2.	Definitions.
                                         In this Subscription Agreement, unless the context otherwise requires:

 

		(a)	“Accredited
                                         Investor Certificate” means the Accredited Investor Certificate in the form
                                         attached hereto as Schedule A which is required to be completed by a Subscriber who is
                                         a resident of the United States;

 

		(b)	“affiliate”
                                         means with respect to another issuer, an issuer if one of them is the subsidiary of the
                                         other, or each of them is controlled by the same person;

 

		(c)	“Applicable
                                         Securities Laws” means, collectively, the applicable securities laws of the
                                         relevant jurisdictions, the regulations, rules, rulings and orders made thereunder, the
                                         applicable policy statements issued by the securities regulators thereunder, the securities
                                         legislation and policies of each other relevant jurisdiction and the rules of the relevant
                                         stock exchange, in each case in effect from time to time;

 

		(d)	“Business
                                         Day” means any day other than a Saturday, Sunday or any other day on which
                                         principal chartered banks located in the City of Toronto are not open for business;

 

		(e)	“Conversion
                                         Price” means, subject to adjustment as provided in the Debenture, $5.42 per
                                         Common Share.

 

		(f)	“Closing”
                                         means the completion of the issue and sale by the Corporation and the purchase by the
                                         Subscribers of the Debentures and Warrants pursuant to the subscription agreements, in
                                         the form of this Subscription Agreement, completed by Subscribers;

 

		(g)	“Closing
                                         Date” has the meaning ascribed thereto in Section 7;

 

		(h)	“Closing
                                         Time” means 1:00 p.m. (Toronto time) on the Closing Date or such other time
                                         as the Corporation may determine;

 

		(i)	“Common
                                         Shares” means common shares in the capital of the Corporation;

 

		(j)	“Designated
                                         Provinces” means each of the provinces of Canada;

 

		(k)	“Disclosed
                                         Principal” mean a principal for whom the Subscriber is purchasing as disclosed
                                         on the face page of this Subscription Agreement;

 

		(l)	“distribution”
                                         and “insider” have the respective meanings ascribed to them in the
                                         Securities Act (Ontario);

 

		(m)	“Event
                                         of Default” has the meaning ascribed thereto in Schedule “E” attached
                                         hereto;

 

		(n)	“International
                                         Jurisdiction” has the meaning ascribed thereto in Section 9(e);

 

		(o)	“material”
                                         means material in relation to the Corporation and its subsidiaries, considered on a consolidated
                                         basis;

 

		(p)	“Maturity
                                         Date” means the earlier of (i) November 13, 2025; (ii) the date the Corporation
                                         completes a Qualified Financing; or (iii) , or (iii) such earlier date as the principal
                                         amount hereof may become due, subject to and in accordance with the terms, conditions
                                         and provisions hereof;

 

		(q)	“NI
                                         45-106” means National Instrument 45-106 - Prospectus Exemptions;

 

		(r)	“Offered
                                         Securities” any equity or voting securities, or securities convertible into
                                         or exchangeable for equity or voting securities, of the Corporation;

 

    	 

    	6

    

 

		(s)	“person”
                                         includes an individual, a corporation, a partnership, trust, fund and an association,
                                         syndicate, organization or other organized group of persons, whether incorporated or
                                         not and an individual or other person in that person’s capacity as a trustee, executor,
                                         administrator or personal or other legal representative;

 

		(a)	“Personal
                                         Information” means any information about a person (whether an individual or
                                         otherwise) and includes information contained in this Subscription Agreement, including
                                         the schedules incorporated by reference herein;

 

		(t)	“Qualified
                                         Financing” means the sale by the Corporation of $2,000,000 or more of Offered
                                         Securities in the aggregate, in one or more closings or tranches.

 

		(u)	“Securities
                                         Commissions” means, collectively, the applicable securities commission or other
                                         securities regulatory authority in each of the Designated Provinces, the United States
                                         or in any International Jurisdiction;

 

		(v)	“Subscriber”
                                         means a subscriber for Debentures and “Subscribers” means all subscribers
                                         for the Debentures including the Subscriber;

 

		(w)	“Subscription
                                         Amount” means the aggregate subscription amount for Debentures as more particularly
                                         set forth on the face page hereof, subscribed for and paid for pursuant to this Subscription
                                         Agreement;

 

		(x)	“Term
                                         Sheet” means the term sheet attached hereto as Schedule D;

 

		(y)	“United
                                         States” or “U.S.” means the United States of America, its
                                         territories and possessions, and any state of the United States and the District of Columbia;

 

		(z)	“U.S.
                                         Person” shall have the meaning ascribed to such term in Rule 902(k) of Regulation
                                         S under the U.S. Securities Act;

 

		(aa)	“U.S.
                                         Securities Act” means the United States Securities Act of 1933, as amended;

 

		(bb)	“Warrants”
                                         has the meaning ascribed thereto in Section 1 hereof; and

 

		(cc)	“Warrant
                                         Shares” has the meaning ascribed thereto in Section 1 hereof.

 

		3.	Description
                                         of Offering.

 

		(a)	The
                                         Debenture Unit is comprised of the Debenture and the Warrants;

 

		(b)	The
                                         Debenture is an unsecured convertible debenture and shall evidence indebtedness of the
                                         Corporation to the holder thereof in the principal amount stated on the Debenture certificate
                                         and such principal amount shall be equal to the Principal Amount.

 

		(c)	Interest
                                         shall accrue on the Principal Amount at a rate of 5% per annum, increasing to 12% per
                                         annum upon an Event Of Default (as such term is defined in the Debenture, attached hereto
                                         as Schedule “E”) until the Event of Default is cured, in Canadian dollars,
                                         with interest to be paid annually in cash in arrears on each anniversary of the Closing
                                         Date, until the Principal Amount is paid off in full.

 

		(d)	The
                                         Debenture shall be convertible into Common Shares, in whole or in part, at the option
                                         of the Debenture holder, at the Conversion Price, during the period beginning six (6)
                                         months after the Closing Date and ending upon the repayment of the Debenture in full.

 

    	 

    	7

    

 

		(e)	The
                                         Corporation may prepay any amount of the Principal Amount of the Debenture during the
                                         initial 120 day period after the Closing Date without penalty. After 120 days following
                                         the Closing Date, if the Corporation elects to prepay the Debenture prior to November
                                         13, 2021, an additional prepayment penalty equal to 35% of the Principal Amount of the
                                         Debenture is required to be paid by the Corporation (“Penalty Payment”).
                                         The Payment Penalty will be satisfied by the Corporation in cash, and the Corporation
                                         shall not under any circumstances satisfy the Penalty Payment with the issuance of common
                                         shares.

 

		(f)	If
                                         there is an Event of Default, the Debenture may be converted into Common Shares at the
                                         Conversion Price at the option of the Debenture holder, and an additional penalty equal
                                         to 40% of the Principal Amount of the Debenture is required to be paid by the Corporation
                                         (the “Default Payment Penalty”). The Default Payment Penalty, if applicable,
                                         will be satisfied by the Corporation in cash, and the Corporation shall not under any
                                         circumstances satisfy the Default Penalty Payment with the issuance of common shares.

 

		(g)	The
                                         description of the Debenture in this Subscription Agreement is a summary only and is
                                         subject to the detailed provisions of the certificates representing the Debenture pursuant
                                         to which such Debenture is to be issued.

 

		(h)	The
                                         Warrants entitle the holder thereof to purchase up to 69,188 Warrant Shares of the Corporation
                                         for a period of five (5) years from the Closing Date at a price of C$5.42 per Warrant
                                         Share (subject to adjustment in certain circumstances).

 

		(i)	The
                                         description of the Warrants in this Subscription Agreement is a summary only and is subject
                                         to the detailed provisions of the certificates representing the Warrants pursuant to
                                         which such Warrants are to be issued.

 

		4.	Delivery
                                         and Payment. The Subscriber agrees that the following shall be delivered to Bennett
                                         Jones LLP, 3400 One First Canadian Place, P.O. Box 130, Toronto, ON, M5X 1A4, not later
                                         than 4:00 p.m. (Toronto Time) Attention: Jessie Lewis Fax No: 416-863-1716 E-mail: LewisJ@bennettjones.com,
                                         not later than 4:00 p.m. (Toronto Time) on the day that is not less than one business
                                         day prior to the Closing Date or such other date or place as the Corporation may advise:

 

		(a)	a
                                         completed and duly signed copy of this Subscription Agreement;

 

		(b)	a
                                         duly completed Schedule “A” – the United States Accredited Investor
                                         Representation Letter, including Appendix “1” and, if applicable, Appendix
                                         “2”, to the Schedule “A” – the Form of U.S. Accredited
                                         Investor Status Certificate

 

		(c)	if
                                         you are not an individual, Schedule C and if applicable Form 4C of the TSX Venture Exchange
                                         contained therein;

 

		(d)	a
                                         duly completed Form 2A of the TSX Venture Exchange, located at: https://www.tmx.com/pif;

 

		(e)	any
                                         other documents required by applicable Securities Laws which the Corporation may request;
                                         and

 

		(f)	the
                                         aggregate Subscription Amount payable by the Subscriber for the Subscriber’s Debenture
                                         Unit subscribed for under this Subscription Agreement, paid by a certified cheque or
                                         bank draft drawn on a Canadian chartered bank made payable to “Bennett Jones LLP
                                         in trust for BriaCell Therapeutics Corp.”, or by wire transfer to Bennett Jones
                                         LLP in trust for paid by wire transfer to BriaCell Therapeutics Corp. pursuant to the
                                         wiring instructions set out on the cover page.

 

    	 

    	8

    

 

The
Subscriber acknowledges and agrees that such documents, when executed and delivered by the Subscriber, will form part of and will
be incorporated into this Subscription Agreement and each shall constitute a representation and warranty or covenant of the Subscriber
hereunder in favour of the Corporation. The Subscriber consents to the filing of such documents as may be required to be filed
with any securities regulatory authority in connection with the transactions contemplated hereby. Subject to the terms and conditions
contained in this Subscription Agreement, the Subscriber acknowledges and agrees that this offer, the aggregate Subscription Amount
and any other documents delivered in connection herewith will be held by the Corporation’s counsel, in trust, until such
time as the conditions set out in this Subscription Agreement are satisfied by the Corporation.

 

		5.	Closing.
                                         The transactions contemplated hereby will be completed at the Closing at the offices
                                         of Bennett Jones LLP, 3400 One First Canadian Place, P.O. Box 130, Toronto, ON, M5X 1A4
                                         at the Closing Time.

 

If,
at the Closing Time, the terms and conditions contained in this Subscription Agreement have been complied with to the satisfaction
of the Corporation, or waived by the Corporation, the Corporation, upon receipt of all completed and executed Subscription Agreements
in respect of the Offering and the aggregate subscription proceeds in respect of the Offering, will deliver or cause to be delivered
to the Subscriber certificates evidencing ownership of the Debenture and Warrants so purchased, and such other documentation and
securities as may be required pursuant to this Subscription Agreement.

 

If,
prior to the Closing Time, the terms and conditions contained in this Subscription Agreement (other than delivery by the Corporation
to the Subscriber of the Debenture and Warrants), have not been complied with to the satisfaction of the Corporation, or waived
by it, the Corporation and the Subscriber will have no further obligations under this Subscription Agreement.

 

		6.	Representations,
                                         Warranties and Covenants of the Corporation. The Corporation represents and warrants
                                         to, and covenants with the Subscriber that, except as set out expressly in any specific
                                         subsection below, as of the date of this Subscription Agreement;

 

		(a)	the
                                         Corporation is a valid and subsisting corporation duly organized and in good standing
                                         under the laws of the Province of British Columbia;

 

		(b)	the
                                         Corporation has full power and authority to enter into and perform this Subscription
                                         Agreement and to do all other acts which are necessary to consummate the transactions
                                         contemplated in the Subscription Agreement;

 

		(c)	the
                                         Corporation is a “reporting issuer” in British Columbia and Alberta and the
                                         Common Shares are listed and posted for trading on the TSX Venture Exchange;

 

		(d)	no
                                         order ceasing or suspending trading in the securities of the Corporation nor prohibiting
                                         sale of such securities has been issued to the Corporation or its directors, officers
                                         or promoters and, to the knowledge of the Corporation, no investigations or proceedings
                                         for such purposes are pending or threatened;

 

		(e)	the
                                         Corporation has complied and will fully comply with the requirements of applicable securities
                                         and corporate legislation in respect of the Offering;

 

		(f)	the
                                         issuance and sale of the Debenture and Warrants does not and will not conflict with and
                                         does not and will not result in a breach of any of the terms, conditions, or provisions
                                         of the constating documents of the Corporation or any agreement or instrument to which
                                         the Corporation is a party or by which its assets are affected;

 

    	 

    	9

    

 

		(g)	this
                                         Subscription Agreement has been or will be at the Closing, duly authorized by all necessary
                                         corporate action on the part of the Corporation, and constitutes a valid obligation of
                                         the Corporation legally binding upon it and enforceable against the Corporation in accordance
                                         with its terms subject to applicable bankruptcy, insolvency, reorganization, moratorium
                                         and other laws of general application affecting the enforcement of creditors’ rights
                                         generally and as limited by laws relating to the availability of equitable remedies;

 

		(h)	the
                                         Common Shares and Warrant Shares, upon payment in full therefor, will, at the time of
                                         issue, be duly allotted, validly issued, fully paid and non-assessable and will be free
                                         of all liens, charges and encumbrances;

 

		(i)	on
                                         the Closing, the approvals from the TSX Venture Exchange that are required for the transactions
                                         herein contemplated to occur at Closing will have been obtained other than any post-Closing
                                         filings required by the TSX Venture Exchange or under applicable Securities Laws; and

 

		(j)	The
                                         Corporation covenants and agrees that if, at any time prior to the Maturity Date, the
                                         Corporation proposes to file a registration statement with respect to any class of equity
                                         or equity-related securities (other than in connection with an offering to the Corporation’s
                                         employees (e.g., Form S-8), or in connection with an acquisition, merger or similar transaction
                                         (e.g., Form S-4), under the U.S. Securities Act in a primary registration on behalf of
                                         the Corporation and/or in a secondary registration on behalf of holders of such securities,
                                         and the registration form to be used may be used for the resale of the Common Shares,
                                         the Corporation will include such Common Shares (i) not previously sold or transferred
                                         by the Subscriber (i.e., held by the original Subscriber); or (ii) not otherwise able
                                         to be freely sold by the Subscriber pursuant to the requirements of Rule 144 of the U.S.
                                         Securities Act (such remaining Common Shares, the “Registrable Securities”),
                                         in such registration statement or give prompt written notice to the Subscriber of its
                                         intention to file a registration statement and will offer to include in such registration
                                         statement, such number of Registrable Securities with respect to which the Subscriber
                                         has received written requests for inclusion therein within twenty (20) days after the
                                         giving of notice by Corporation (the “Piggyback Registration Rights”).
                                         The Subscriber acknowledges and understands that the Corporation may file a primary or
                                         secondary registration on behalf of certain investors that have provided or will provide
                                         financing or other resources to the Corporation, that the inclusion of the Registrable
                                         Securities in such registration is subject to the prior approval of such investors, and
                                         that such investors may not approve the inclusion of the Registrable Securities, in which
                                         case, the Piggyback Registration Rights provided in this paragraph will continue pursuant
                                         to the terms of this paragraph for any subsequent primary or secondary registration.
                                         The Subscriber also agrees that the Corporation may be limited in its ability to register
                                         all of the Registrable Securities on a single registration statement pursuant to Rule
                                         415 of the U.S. Securities Act and consents and agrees to the Corporation registering
                                         less than all of the Registrable Securities in the event the Corporation is precluded
                                         from registering all of the Registrable Securities pursuant to Rule 415 (or any other
                                         rule or regulation promulgated by the Securities and Exchange Commission). Notwithstanding
                                         the requirements of this Section (j), the Piggyback Registration Rights shall not apply
                                         to offerings by the Corporation on Form S-3 (or pursuant to prospectus supplements filed
                                         to Form S-3’s), unless the Corporation files a resale registration on Form S-3.

 

    	 

    	10

    

 

		7.	Conditions
                                         and Closing. The Closing shall occur on or before November 13, 2020, or on such other
                                         date as may be determined by the Corporation (the “Closing Date”).

 

The
Closing (including the closing of this Subscription) is conditional upon and subject to:

 

		(a)	payment
                                         by the Subscriber (in form acceptable to the Corporation) of the Subscription Amount
                                         in immediately available funds;

 

		(b)	the
                                         Subscriber having properly completed, signed and delivered to the Corporation this Subscription
                                         Agreement, including any applicable Schedules, and all other documentation contemplated
                                         by this Subscription Agreement;

 

		(c)	the
                                         Corporation accepting the Subscriber’s subscription, in whole or in part;

 

		(d)	the
                                         Corporation having obtained all necessary approvals and consents, including regulatory
                                         approvals and approvals from the TSX Venture Exchange for the Offering;

 

		(e)	the
                                         Corporation having obtained approval of the terms of the Offering from a majority of
                                         the disinterested shareholders of the Corporation;

 

		(f)	the
                                         issue and sale of the Debenture and Warrants being exempt from the requirement to file
                                         a prospectus or deliver an offering memorandum (as defined in Applicable Securities Laws,
                                         including Ontario Securities Commission Rule 14-501 - Definitions) and the requirement
                                         to deliver an offering memorandum under Applicable Securities Laws relating to the sale
                                         of the Debenture and the Warrants, or the Corporation having received such orders, consents
                                         or approvals as may be required to permit such sale without the requirement to file a
                                         prospectus or deliver an offering memorandum; and

 

		(g)	the
                                         representations and warranties of the Subscriber being true and correct as at the Closing
                                         Time.

 

The
Subscriber acknowledges and agrees that as the sale of the Subscriber’s Debenture and Warrants will not be qualified by
a prospectus, such sale is subject to the condition that the Subscriber (or, if applicable, any others for whom the Subscriber
is contracting hereunder) sign and return to the Corporation all relevant documentation required by Applicable Securities Laws.

 

		8.	Acceptance
                                         or Rejection. The Corporation will have the right to accept or reject this subscription
                                         in whole or in part at any time at any time at or prior to the Closing Time. The Subscriber
                                         acknowledges and agrees that the acceptance of this subscription will be conditional
                                         upon the issue and sale of the Debenture and Warrants to the Subscriber and the Common
                                         Shares and Warrant Shares underlying such Debenture and Warrants, respectively, being
                                         exempt from any requirement to file a prospectus or offering memorandum or any similar
                                         document under Applicable Securities Laws. The Corporation will be deemed to have accepted
                                         this subscription upon the Corporation’s execution of the acceptance form at the
                                         beginning of this Subscription Agreement and the delivery at the Closing of the certificate
                                         or evidence of electronic delivery representing the Subscriber’s Debenture and
                                         Warrants in accordance with the provisions hereof.

 

    	 

    	11

    

 

		9.	Subscriber’s
                                         Representations, Warranties & Acknowledgments. The Subscriber (on its own behalf
                                         and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
                                         represents, warrants, covenants and acknowledges to the Corporation as follows and acknowledges
                                         that the Corporation and its counsel are relying on such representations, warranties
                                         and covenants in connection with the transactions contemplated in, and entry into by
                                         the Corporation of this Subscription Agreement, that both at the date hereof and at the
                                         Closing Time:

 

		(a)	The
                                         Subscriber (including, if applicable, each Disclosed Principal) was offered the Debenture
                                         Unit in, and is resident, or if not an individual has its head office in, the jurisdiction
                                         set out on the face page of this Subscription Agreement, and intends the applicable Securities
                                         Laws of that jurisdiction to govern the offer, sale and issuance of the Debenture and
                                         the Warrants to the Subscriber. Such address was not created and is not used solely for
                                         the purpose of acquiring the Debenture and the Warrants and the Subscriber was solicited
                                         to purchase in such jurisdiction. The Subscriber and any beneficial purchaser for whom
                                         it is acting was not created or used solely to purchase or hold the Debenture and the
                                         Warrants in reliance upon an exemption from the prospectus requirements as set out in
                                         NI 45-106.

 

		(b)	The
                                         Subscriber has properly completed, executed and delivered to the Corporation this Subscription
                                         Agreement and Schedule “A” – the United States Accredited Investor
                                         Representation Letter, including Appendix “1” to Schedule “A”
                                         – the Form of U.S. Accredited Investment Status Certificate, as applicable and
                                         the representations, warranties, covenants, and information contained herein and therein
                                         are true and correct as of the date hereof and will be true and correct as of the Closing.

 

		(c)	The
                                         Subscriber (including, if applicable, each Disclosed Principal) will not offer, sell
                                         or otherwise dispose of the Debenture, the underlying Common Shares, the Warrants, or
                                         the underlying Warrant Shares in the United States or to a U.S. Person unless such offer,
                                         sale or disposition is made in accordance with an exemption from the registration requirements
                                         under the U.S. Securities Act and the Securities Laws of all applicable states of the
                                         United States or the U.S. Securities and Exchange Commission has declared effective a
                                         registration statement in respect of such securities.

 

		(d)	The
                                         execution and delivery of this Subscription Agreement, the performance and compliance
                                         with the terms hereof, the subscription for the Debenture Unit and the completion of
                                         the transactions described herein by the Subscriber will not result in any material breach
                                         of, or be in conflict with, or constitute a material default under, or create a state
                                         of facts that, after notice or lapse of time, or both, would constitute a material default
                                         under any term or provision of the constating documents, by-laws or resolutions of the
                                         Subscriber (if applicable), the Securities Laws or any other laws applicable to the Subscriber,
                                         any agreement to which the Subscriber is a party, or any judgment, decree, order, statute,
                                         rule or regulation applicable to the Subscriber.

 

		(e)	The
                                         Subscriber is subscribing for the Debenture and the Warrants as principal for its own
                                         account and not for the benefit of any other person (within the meaning of all Applicable
                                         Securities Laws) or it is subscribing as agent for a Disclosed Principal, as disclosed
                                         on the face page of this Subscription Agreement, and acknowledges that the Corporation
                                         may be required by law to collect, use and disclose the Personal Information of the Subscriber
                                         (including, if applicable, any Disclosed Principal) and consents (including, if applicable,
                                         on behalf of any Disclosed Principal) to such collection, use and disclosure to certain
                                         regulatory authorities (including stock exchanges).

 

		(f)	In
                                         the case of a subscription for the Debenture and the Warrants by the Subscriber acting
                                         as trustee or agent for a fully managed account or as agent for a Disclosed Principal,
                                         the Subscriber is duly authorized to execute and deliver this Subscription Agreement
                                         and all other necessary documentation in connection with such subscription on behalf
                                         of the fully managed account or Disclosed Principal, as applicable, and this Subscription
                                         Agreement has been duly authorized, executed and delivered by or on behalf of and constitutes
                                         a legal, valid and binding agreement of, the fully managed account or Disclosed Principal,
                                         as applicable.

 

    	 

    	12

    

 

		(g)	In
                                         the case of a subscription for the Debenture Unit by the Subscriber acting as principal,
                                         this Subscription Agreement has been duly authorized, executed and delivered by, and
                                         constitutes a legal, valid and binding agreement of, the Subscriber. This Subscription
                                         Agreement is enforceable in accordance with its terms against the Subscriber.

 

		(h)	If
                                         the Subscriber is a corporation, the Subscriber is duly incorporated and is validly subsisting
                                         under the laws of its jurisdiction of incorporation and has all requisite legal and corporate
                                         power and authority to execute and deliver this Subscription Agreement, to subscribe
                                         for the Debenture and the Warrants as contemplated herein and to carry out and perform
                                         its obligations under the terms of this Subscription Agreement; a partnership, limited
                                         liability company, syndicate or other form of unincorporated organization, the Subscriber
                                         has the necessary legal capacity and authority to execute and deliver this Subscription
                                         Agreement and to observe and perform its covenants and obligations hereunder and has
                                         obtained all necessary approvals in respect thereof; or an individual, the Subscriber
                                         is of the full age of majority in the jurisdiction in which the Subscription agreement
                                         is executed and has all requisite legal capacity and competence to execute and deliver
                                         this Subscription Agreement and to observe and perform his or her covenants and obligations
                                         hereunder and, in any case, upon acceptance by the Corporation, this Subscription Agreement
                                         will constitute a legal, valid and binding agreement of the Subscriber enforceable against
                                         the Subscriber in accordance with its terms and will not result in a violation of, or
                                         create a state of facts which, after notice, lapse of time or both, would constitute
                                         a default or breach of, any of the Subscriber’s, constating documents, by-laws
                                         or authorizing resolutions (if applicable), any agreement to which the Subscriber, is
                                         a party or by which it is bound or any law applicable to the Subscriber, or any judgment,
                                         decree, order, statute, rule or regulation applicable to the Subscriber.

 

		(i)	There
                                         is no person acting or purporting to act in connection with the Offering who is entitled
                                         to any brokerage or finder’s fee. If any person establishes a claim that any fee
                                         or other compensation is payable in connection with this subscription for the Debenture
                                         and the Warrants, the Subscriber covenants to indemnify and hold harmless the Corporation
                                         with respect thereto and with respect to all costs reasonably incurred in the defence
                                         thereof.

 

		(j)	If
                                         required by Applicable Securities Laws or the Corporation, the Subscriber will execute,
                                         deliver and file, or assist the Corporation in filing, such reports, undertakings and
                                         other documents with respect to the issue and/or sale of the Debenture and the Warrants
                                         as may be required by any Securities Commission, stock exchange or other regulatory authority.

 

		(k)	The
                                         Subscriber (including, if applicable, each Disclosed Principal) has been advised to consult
                                         its own legal advisors with respect to trading in the Debenture, the Common Shares, the
                                         Warrants, and the underlying Warrant Shares, and with respect to the resale restrictions
                                         imposed by the Applicable Securities Laws of the jurisdiction in which the Subscriber
                                         resides and other Applicable Securities Laws, and acknowledges that no representation
                                         has been made respecting the applicable hold periods imposed by the Applicable Securities
                                         Laws or other resale restrictions applicable to such securities which restrict the ability
                                         of the Subscriber (or others for whom it is contracting hereunder) to resell such securities,
                                         that the Subscriber (including, if applicable, each Disclosed Principal) is solely responsible
                                         to find out what these restrictions are and the Subscriber is solely responsible (and
                                         the Corporation is not in any way responsible) for compliance with applicable resale
                                         restrictions and the Subscriber is aware that it (and, if applicable, each Disclosed
                                         Principal) may not be able to resell such Debenture, underlying Common Shares, Warrants,
                                         or underlying Warrant Shares except in accordance with limited exemptions under the Applicable
                                         Securities Laws and other applicable laws. The Subscriber also acknowledges the legend
                                         restriction notation applicable to the resale of the Debenture, the underlying Common
                                         Shares, the Warrants, and the underlying Warrant Shares, as set out below. 

 

    	 

    	13

    

 

	 	(l)	The
    Subscriber (including, if applicable, each Disclosed Principal) has not received, nor has it requested, nor does it have any
    need to receive, a prospectus, registration statement or offering memorandum, within the meaning of the Securities Laws, or
    any sales or advertising literature in connection with the Offering or any document purporting to describe the business and
    affairs of the Corporation which has been prepared for review by prospective purchasers to assist in making an investment
    decision in respect of the Debenture and the Warrants, and the Subscriber’s decision to subscribe for the Debenture
    and the Warrants was not based upon, and the Subscriber has not relied upon, any verbal or written representations as to facts
    made by or on behalf of the Corporation. The Subscriber’s decision to subscribe for the Debenture and the Warrants was
    based solely upon this Subscription Agreement, including the Term Sheet, and information about the Corporation which is publicly
    available.
	 	 	 
	 	(m)	Except
    for its knowledge regarding its subscription for the Debenture and Warrants hereunder, the Subscriber has no knowledge of
    a “material fact” or a “material change” (as those terms are defined in the Securities Act
    (Ontario) and which generally means a fact or change which would reasonably be expected to have a significant effect on the
    market price of the Common Shares) in the affairs of the Corporation that has not been generally disclosed. 
	 	 	 
	 	(n)	No
    person has made any written or oral representations:

 

	 	(i)	that
    any person will resell or repurchase the Debenture, the underlying Common Shares, the Warrants or the underlying Warrant Shares,
	 	 	 
	 	(ii)	that
    any person will refund the Subscription Amount; or
	 	 	 
	 	(iii)	as
    to the future price or value of the Debenture, the underlying Common Shares, the Warrants or the underlying Warrant Shares.

 

	 	(o)	The
    subscription for the Debenture and the Warrants has not been made through or as a result of, and the distribution of the Debentures
    and the Warrants is not being accompanied by any general solicitation or advertisement, including without limitation in printed
    public media, radio, television or telecommunications, including electronic display, or as part of a general solicitation.
	 	 	 
	 	(p)	There
    are risks associated with the purchase of and investment in the Debenture and the Warrants and the Subscriber has such knowledge
    and experience that it is capable of evaluating the merits and risks of an investment in the Debenture and the Warrants and
    fully understands the restrictions on resale of the Debenture, the underlying Common Shares, the Warrants, and the underlying
    Warrant Shares and is capable of bearing the economic risk of the investment.
	 	 	 
	 	(q)	The
    funds representing the Subscription Amount that will be advanced by the Subscriber to the Corporation hereunder will not represent
    proceeds of crime for the purposes of the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada)
    (the “PCMLTFA”) and the Subscriber acknowledges that the Corporation or its advisors may in the future
    be required by law to disclose the Subscriber’s name and other information relating to this Subscription Agreement and
    the Subscriber’s subscription hereunder, on a confidential basis, pursuant to the PCMLTFA. To the best of the Subscriber’s
    knowledge (a) none of the Subscription Amount to be provided by the Subscriber (i) has been or will be derived from or related
    to any activity that is deemed criminal under the law of Canada, the United States, or any other jurisdiction, or (ii) is
    being tendered on behalf of a person or entity who has not been identified to the Subscriber, and (b) the Subscriber shall
    promptly notify the Corporation if the Subscriber discovers that any of such representations ceases to be true, and to provide
    the Corporation with appropriate information in connection therewith. None of the funds the Subscriber is using to purchase
    the Debenture and Warrants are, to the knowledge of the Subscriber, proceeds obtained or derived, directly or indirectly,
    as a result of illegal activities.

 

    	 

    	14

    

 

	 	(r)	The
    Subscriber has not received from the Corporation any financial assistance of any kind, directly or indirectly, in connection
    with its purchase of the Debenture and Warrants hereunder.
	 	 	 
	 	(s)	The
    Subscriber (i) is not either an “insider” of the Corporation or a “registrant” (each as defined under
    Applicable Securities Laws) or, (ii) has identified itself to the Corporation as either an “insider” of the Corporation
    or a “registrant” (each as defined under Applicable Securities Laws).
	 	 	 
	 	(t)	The
    Subscriber has accurately disclosed on the cover page of this Subscription Agreement, their ownership, directly or indirectly,
    of any securities of the Corporation as of the date of this Subscription Agreement, including, but not limited to, their direct
    or indirect ownership of Common Shares, Warrants, Debentures and options of the Corporation.
	 	 	 
	 	(u)	Legal
    counsel retained by the Corporation is acting as counsel to the Corporation and not as counsel to the Purchaser and the Purchaser
    may not rely upon such counsel in any respect. The Purchaser should obtain independent legal advice with respect to the investment
    in the Debenture Unit.

 

	10.	Acknowledgements
    and Covenants of the Subscriber. The Subscriber, on its own behalf and, if applicable on behalf of others for whom it
    is acting hereunder, hereby acknowledges, covenants and agrees as follows:

 

	 	(a)	It
    has received and reviewed a copy of the Term Sheet setting out the principal terms of the Offering.
	 	 	 
	 	(b)	No
    Securities Commission, agency, governmental authority, regulatory body, stock exchange or other regulatory body or similar
    regulatory authority has reviewed or passed on the merits of the Debenture and the Warrants.
	 	 	 
	 	(c)	The
    Subscriber acknowledges that the Debenture, the underlying Common Shares, the Warrants and the underlying Warrant Shares have
    not been, and will not be, registered under the U.S. Securities Act and may not be offered or sold in the United States or
    to a U.S. Person unless the Debenture, the underlying Common Shares, the Warrants and the underlying Warrant Shares are registered
    under the U.S. Securities Act and all applicable state Securities Laws or an exemption from such registration requirements
    is available, and further agrees that hedging transactions involving such Common Shares may not be conducted unless in compliance
    with the U.S. Securities Act. 
	 	 	 
	 	(d)	The
    Debenture, the underlying Common Shares, the Warrants and the underlying Warrant Shares shall be subject to statutory resale
    restrictions under the Applicable Securities Laws of the jurisdiction in which the Subscriber resides and under other Applicable
    Securities Laws, and the Subscriber covenants that it will not resell the Debenture, the underlying Common Shares, the Warrants,
    or the underlying Warrant Shares except in compliance with such laws and the Subscriber acknowledges that it is solely responsible
    for such compliance.

 

    	 

    	15

    

 

	 	(e)	The
    ability to transfer the Debenture, the underlying Common Shares, the Warrants, and the underlying Warrant Shares is limited
    by, among other things, Applicable Securities Laws and the Corporation shall refuse, and shall instruct its transfer agent
    to refuse to register any transfer that does not comply with the Applicable Securities Laws. It is the responsibility of the
    Subscriber to find out what the transfer restrictions are and to comply with them before selling their securities.
	 	 	 
	 	(f)	None
    of the Corporation or any of its officers, directors, employees, shareholders, representatives, affiliates, related entities
    and associates, or any persons acting on its or their behalf, will in any circumstances be liable to the Subscriber under,
    arising out of, or in any way connected with this Subscription Agreement for any indirect or consequential loss or damage
    whether arising in contract or tort.
	 	 	 
	 	(g)	The
    Debenture, the underlying Common Shares, the Warrants, and the underlying Warrant Shares shall have attached to them, as of
    the Closing Date, the legends substantially in the following form and with the necessary information inserted:

 

“UNLESS
PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE MARCH 14, 2021”

 

“THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED
(THE “U.S. SECURITIES ACT”) OR U.S. STATE SECURITIES LAWS. THESE SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED, DIRECTLY OR INDIRECTLY, ONLY (A) TO BRIACELL THERAPEUTICS CORP. (THE “CORPORATION”), (B) OUTSIDE THE
UNITED STATES IN COMPLIANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE LOCAL
LAWS AND REGULATIONS, (C) IN COMPLIANCE WITH THE EXEMPTION FROM THE REGISTRATION REQUIREMENTS UNDER THE U.S. SECURITIES ACT PROVIDED
BY (I) RULE 144 THEREUNDER IF AVAILABLE OR (II) RULE 144A THEREUNDER, IF AVAILABLE, AND IN EACH CASE IN ACCORDANCE WITH APPLICABLE
U.S. STATE SECURITIES LAWS, (D) IN ANOTHER TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY
APPLICABLE STATE SECURITIES LAWS, OR (E) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE U.S. SECURITIES ACT, PROVIDED
THAT, IN THE CASE OF TRANSFERS PURSUANT TO (C)(I) OR (D) ABOVE, THE HOLDER HAS, PRIOR TO SUCH TRANSFER, FURNISHED TO THE CORPORATION
AN OPINION OF COUNSEL OR OTHER EVIDENCE OF EXEMPTION, IN EITHER CASE REASONABLY SATISFACTORY TO THE CORPORATION. DELIVERY OF THIS
CERTIFICATE MAY NOT CONSTITUTE “GOOD DELIVERY” IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA.”

 

and
if required:

 

    	 

    	16

    

 

“WITHOUT
PRIOR WRITTEN APPROVAL OF THE TSX VENTURE EXCHANGE AND COMPLIANCE WITH ALL APPLICABLE SECURITIES LEGISLATION, THE SECURITIES REPRESENTED
BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE TRADED ON OR THROUGH THE FACILITIES OF THE TSX VENTURE
EXCHANGE OR OTHERWISE IN CANADA OR TO OR FOR THE BENEFIT OF A CANADIAN RESIDENT MARCH 14, 2021. ”

 

	 	(h)	The
    Subscriber, and each Disclosed Principal, if applicable, shall execute, deliver, file and otherwise assist the Corporation
    with filing all documentation required by the applicable Securities Laws to permit the subscription for the Debenture and
    Warrants and the issuance of the Debenture and the Warrants and the listing of the underlying Common Shares and Warrant Shares
    on the TSX Venture Exchange.
	 	 	 
	 	(i)	The
    Corporation is relying on an exemption from the requirement to provide the Subscriber with a prospectus under applicable Securities
    Laws and, as a consequence of acquiring the Debenture and the Warrants pursuant to such exemption:

 

	 	(i)	certain
    protections, rights and remedies provided by applicable Securities Laws, including statutory rights of rescission and certain
    statutory remedies against an issuer, underwriters, auditors, directors and officers that are available to investors who acquire
    securities offered by a prospectus, will not be available to the Subscriber, 
	 	 	 
	 	(ii)	the
    common law may not provide investors with an adequate remedy in the event that they suffer investment losses in connection
    with securities acquired in a private placement,
	 	 	 
	 	(iii)	the
    Subscriber may not receive information that would otherwise be required to be given under applicable Securities Laws, and
	 	 	 
	 	(iv)	the
    Corporation is relieved from certain obligations that would otherwise apply under applicable Securities Laws.

 

	 	(j)	The
    Subscriber is responsible for obtaining such legal and tax advice as it considers appropriate in connection with the execution,
    delivery and performance of this Subscription Agreement and the transactions contemplated under this Subscription Agreement,
    and the Subscriber is not relying on the Corporation or its affiliates or counsel, in this regard.
	 	 	 
	 	(k)	There
    is no government guarantee or insurance covering the Debenture and the Warrants.
	 	 	 
	 	(l)	There
    are risks associated with the purchase of the Debenture and the Warrants and the Subscriber may lose his, her or its entire
    investment. 
	 	 	 
	 	(m)	This
    Subscription Agreement and the Schedules hereto require the Subscriber to provide certain Personal Information to the Corporation.
    Such information is being collected by the Corporation for the purposes of completing the Offering, which includes, without
    limitation, determining the Subscriber’s eligibility to purchase the Debenture and the Warrants under the Securities
    Laws and other applicable laws, preparing and registering such securities to be issued to the Subscriber and completing filings
    required by any stock exchange, securities regulatory authority or taxation authority. The Subscriber’s Personal Information
    may be disclosed by the Corporation and its advisors to: (a) stock exchanges or securities regulatory authorities, (b) the
    Corporation’s registrar and transfer agent; (c) the Canada Revenue Agency, and (d) any of the other parties involved
    in the Offering, including legal counsel and may be included in record books in connection with the Offering. By executing
    this Subscription Agreement, the Subscriber is deemed to be consenting to the foregoing collection, use and disclosure of
    the Subscriber’s Personal Information. The Subscriber also consents to the filing of copies or originals of this Subscription
    Agreement (including all Schedules) and any other document relating to the Offering as may be required to be filed with any
    stock exchange, securities regulatory authority or taxation authority in connection with the transactions contemplated hereby.
    The Subscriber represents and warrants that it has the authority to provide the consents and acknowledgements set out in this
    paragraph on behalf of each Disclosed Principal, as applicable. 

 

    	 

    	17

    

 

	 	(n)	The
    Subscriber hereby acknowledges and consents to the collection, use, and disclosure of certain Personal Information by the
    British Columbia Securities Commission, including the publishing or otherwise making available to the public, Personal Information
    including, for individuals, their name, number and type of securities purchased, the purchase price therefor, and their insider
    or registrant status, if applicable, and for non-individual Subscribers, the above information and their address, contact
    person name and telephone number and the exemption that the Subscriber is relying on in purchasing the Debenture and the Warrants.
    In the event the Subscriber has any questions with respect to the indirect collection of such information, the Subscriber
    should contact the British Columbia Securities Commission, P.O. Box 10142, Pacific Centre, 701 West Georgia Street, Vancouver,
    British Columbia V7Y 1L2, Telephone: 1-800-373-6393, Facsimile: (604) 899-6581, E-mail: inquiries@bcsc.bc.ca.
	 	 	 
	 	(o)	The
    Subscriber is not a “control person” of the Corporation, as that term is defined in the Securities Act
    (British Columbia), will not become a “control person” of the Corporation by purchasing the Debenture and the
    number of Warrants subscribed for under this Subscription Agreement, and does not intend to act jointly or in concert with
    any other person to form a control group in respect of the Corporation. The Subscriber has not and will not enter into any
    voting trust or similar agreement that has the effect of directing the manner in which the votes attached to the securities
    purchased pursuant to this Subscription Agreement may be voted following the Closing Date. 
	 	 	 
	 	(p)	The
    Subscriber will not resell the Debenture, the underlying Common Shares (if applicable), the Warrants, or the underlying Warrant
    Shares (if applicable) except in accordance with the provisions of Applicable Securities Laws and stock exchange rules, if
    applicable, in the future.
	 	 	 
	 	(q)	The
    Subscriber acknowledges that the Corporation may complete additional financings in the future in order to develop the proposed
    business of the Corporation and to fund its ongoing development; that there is no assurance that such financings will be available
    and, if available, on reasonable terms; any such future financings may have a dilutive effect on current securityholders,
    including the Subscriber; that if such future financings are not available, the Corporation may be unable to fund its ongoing
    development and the lack of capital resources may result in the failure of its business venture.
	 	 	 
	 	(r)	The
    Subscriber acknowledges and agrees that, other than as set forth in the Term Sheet, all costs incurred by the Subscriber (including
    any fees and disbursements of any special counsel retained by the Subscriber) relating to the sale of the Debenture and Warrants
    to the Subscriber shall be borne by the Subscriber.

 

    	 

    	18

    

 

	 	(s)	The
    Subscriber acknowledges that all warranties, conditions, representations or stipulations, whether express or implied and whether
    arising hereunder or under prior agreement or statement or by statute or at common law, are expressly those of the Corporation.
    The Subscriber acknowledges that no information or representation concerning the Corporation has been provided to the Subscriber
    by the Corporation other than those contained in this Subscription Agreement, and that the Subscriber is relying entirely
    upon this Subscription Agreement for any representations or warranties in relation to the Corporation.

 

	11.	Reliance
    on Representations, Warranties, Covenants and Acknowledgements. The Subscriber acknowledges and agrees that the representations,
    warranties, covenants and acknowledgements made by the Subscriber in this Subscription Agreement are made with the intention
    that they may be relied upon by the Corporation and its counsel in determining the Subscriber’s eligibility (and, if
    applicable, the eligibility of others for whom the Subscriber is contracting hereunder) to purchase the Debenture and the
    Warrants under Securities Laws. The Subscriber undertakes to immediately notify the Corporation of any change in any statement
    or other information relating to the Subscriber set forth in this Subscription Agreement that takes place prior to the Closing
    time. The Subscriber further agrees that by accepting the Debenture and the Warrants, the Subscriber shall be representing
    and warranting that such representations, warranties, acknowledgements and covenants are true as at the Closing Time with
    the same force and effect as if they had been made by the Subscriber at the Closing Time.
	 	 
	12.	Survival
    of Representations, Warranties and Covenants of the Subscriber. The representations, warranties and covenants of the Subscriber
    contained in this Subscription Agreement and any certificate or document delivered pursuant to or in connection with this
    Subscription Agreement shall survive the Closing and, notwithstanding such Closing or any investigation made by or on behalf
    of the Corporation with respect thereto, and notwithstanding any subsequent disposition by the Subscriber of the Debenture,
    the underlying Common Shares, the Warrants, or the underlying Warrant Shares, and shall continue in full force and effect
    for the benefit of the Corporation for a period of two years following the Closing Date.
	 	 
	13.	General
    Authorization to Correct Minor Errors. The Subscriber hereby authorizes the Corporation and its counsel to correct any
    minor errors in, or complete any minor information missing from any part of the Subscription Agreement and any other acknowledgements,
    provisions, forms, certificates or documents executed by the Subscriber and delivered to the Corporation in connection with
    the Offering.
	 	 
	14.	No
    Regulatory Endorsement. The Subscriber is aware that no stock exchange or governmental agency, authority, regulatory body,
    Securities Commission or other entity has made any finding or determination as to the merit of investment in, nor has any
    such stock exchange or governmental agency, authority, regulatory body, Securities Commission, or other entity made any recommendation
    or endorsement with respect to the Debenture or Warrants. 
	 	 
	15.	Legal
    and Tax Advice. The Subscriber acknowledges and agrees that it is solely responsible for obtaining such legal advice and
    tax advice as it considers appropriate in connection with the execution, delivery and performance by it of this Subscription
    Agreement and the completion of the transactions contemplated hereby.
	 	 
	16.	No
    Revocation. The Subscriber, on its own behalf and, if applicable, on the behalf of others for whom it is contracting hereunder,
    agrees that this offer is made for valuable consideration and may not be withdrawn, cancelled, terminated or revoked by the
    Subscriber on its own behalf and, if applicable, on behalf of others for whom it is contracting hereunder, without the consent
    of the Corporation.

 

    	 

    	19

    

 

	17.	Indemnity.
    The Subscriber agrees to indemnify and hold harmless the Corporation and its directors, officers, employees, agents, advisers
    and shareholders from and against any and all loss, liability, claim, damage and expense whatsoever (including, but not limited
    to, any and all fees, costs and expenses whatsoever reasonably incurred in investigating, preparing or defending against any
    claim, law suit, administrative proceeding or investigation whether commenced or threatened) arising out of or based upon
    any representation or warranty of the Subscriber contained herein or in any document furnished by the Subscriber to the Corporation
    in connection herewith being untrue in any material respect or any breach or failure by the Subscriber to comply with any
    covenant or agreement made by the Subscriber herein or in any document furnished by the Subscriber to the Corporation in connection
    herewith. The Subscriber represents and warrants that it has the authority to provide the consents and acknowledgements set
    out in this paragraph on behalf of all beneficial purchasers.
	 	 
	18.	Assignment.
    The terms and provisions of this Subscription Agreement shall be binding upon and enure to the benefit of the Subscriber,
    the Corporation and their respective successors and assigns; provided that, except for the assignment by a Subscriber who
    is acting as nominee or agent to the beneficial owner and as otherwise herein provided, this Subscription Agreement shall
    not be assignable by any party without the prior written consent of the other parties. 
	 	 
	19.	Governing
    Law. This Subscription Agreement shall be governed by and construed in accordance with the laws of the Province of Ontario
    and the federal laws of Canada applicable therein. The Subscriber on its own behalf and, if applicable, on behalf of others
    for whom it is contracting hereunder, hereby irrevocably attorns to the jurisdiction of the courts of the Province of Ontario
    with respect to any matters arising out of this Subscription Agreement. 
	 	 
	20.	Facsimile
    Subscriptions and Counterparts. The Corporation shall be entitled to rely on electronic delivery or delivery by facsimile
    machine of an executed copy of this Subscription Agreement, including the completed schedules hereto, and acceptance by the
    Corporation of such electronic or facsimile copy shall be legally effective to create a valid and binding agreement between
    the Subscriber and the Corporation in accordance with the terms hereof. This Subscription Agreement may be executed in any
    number of counterparts, each of which when delivered, either in original, electronic or facsimile form, shall be deemed to
    be an original and all of which together shall constitute one and the same document.
	 	 
	21.	Entire
    Agreement and Modification. This Subscription Agreement (including the schedules hereto) contains the entire agreement
    of the parties hereto relating to the subject matter hereof and there are no representations, covenants or other agreements
    relating to the subject matter hereof except as stated or referred to herein. Subject to the terms hereof, neither this Subscription
    Agreement nor any provision hereof shall be modified, changed, discharged or terminated except by an instrument in writing
    signed by the party against whom any waiver, change, discharge or termination is sought.
	 	 
	22.	Headings.
    The division of this Subscription Agreement into Articles, Sections, Schedules and other subdivisions and the inclusion
    of headings are for convenience of reference only and shall not affect the construction or interpretation of this Subscription
    Agreement. The headings in this Subscription Agreement are not intended to be full or precise descriptions of the text to
    which they refer. Unless something in the subject matter or context is inconsistent therewith, references herein to an Article,
    Section, Subsection, paragraph, clause or Schedule are to the applicable article, section, subsection, paragraph, clause or
    schedule of this Subscription Agreement.
	 	 
	23.	Time
    of Essence. Time is of the essence of this Subscription Agreement.
	 	 
	24.	Effective
    Date. This Subscription Agreement is intended to and shall take effect on the Closing Date, notwithstanding its actual
    date of execution or delivery by any of the parties.
	 	 
	25.	Currency.
    Except if specifically stated otherwise, all dollar amounts herein are in Canadian dollars.
	 	 
	26.	Gender
    and Number. Words importing the singular number only shall include the plural and vice versa, and words importing the
    masculine gender shall include the feminine gender and vice versa. 
	 	 
	27.	Severability.
    If any one or more of the provisions contained in this Subscription Agreement should be invalid, illegal or unenforceable
    in any respect in any jurisdiction, the validity, legality and enforceability of such provision or provisions shall not in
    any way be affected or impaired thereby in any other jurisdiction and the validity, legality and enforceability of the remaining
    provisions contained herein shall not in any way be affected or impaired thereby, unless in either case as a result of such
    determination this Subscription Agreement would fail of its essential purpose.
	 	 
	28.	Language.
    The parties hereto acknowledge and confirm that they have requested that this Subscription Agreement as well as all notices
    and other documents contemplated hereby be drawn up in the English language

 

    	 

    	20

    

 

 

SCHEDULE
“A”

United
States Accredited 

Investor
Representation Letter

 

This
United States Accredited Investor Representation Letter is being delivered in connection with the execution and delivery of the
Subscription Agreement of the undersigned purchaser (the “Purchaser”) in connection with the issuance of a
debenture (the “Debenture”) of BriaCell Therapeutics Corp. (the “Corporation”). Capitalized
terms used herein and not defined herein will have the meanings ascribed thereto in the Subscription Agreement. The Purchaser
represents, warrants and covenants (which representations, warranties and covenants will survive the Closing Date) on its own
behalf and, if applicable, on behalf of any beneficial purchaser for whom the Purchaser is contracting hereunder to the Corporation
and acknowledges that the Corporation and its respective counsel are relying thereon that:

 

	 	(a)	The
    Purchaser understands and acknowledges that the Debenture has not been and will not be registered under the U.S. Securities
    Act or the securities laws of any state of the United States, and that the offer and sale of the Debentures to it are being
    made in reliance upon the exemption from registration provided by Regulation D under the United States Securities Act of 1933,
    as amended (the “U.S. Securities Act”) and similar exemptions under applicable state securities laws.
	 	 	 
	 	(a)	The
    Purchaser is an “accredited investor” as defined in Rule 501(a) of Regulation D under the U.S. Securities Act
    (a “U.S. Accredited Investor”) and has executed and delivered to the Corporation Appendix “1”
    and, if applicable, Appendix “2”, to this Schedule “A” and is acquiring the Debenture for its own
    account and not on behalf of any other person or for the account of a U.S. Accredited Investor with respect to which it exercises
    sole investment discretion and, in either case, not with a view to any resale, distribution or other disposition of the Debenture
    in violation of United States federal or state securities laws.
	 	 	 
	 	(b)	The
    Purchaser acknowledges that it has not purchased the Debenture as a result of any “directed selling efforts” (as
    defined in Regulation S under the U.S. Securities Act (“Regulation S”) or any “general solicitation”
    or “general advertising” (as those terms are used in Regulation D under the U.S. Securities Act), including advertisements,
    articles, notices or other communications published in any newspaper, magazine or similar media or on the Internet, or broadcast
    over radio or television, or the internet, or any seminar or meeting whose attendees have been invited by general solicitation
    or general advertising.
	 	 	 
	 	(c)	The
    Purchaser understands and acknowledges that the Debenture will be “restricted securities” within the meaning of
    Rule 144(a)(3) under the U.S. Securities Act, and agrees that if it decides to offer, sell, pledge or otherwise transfer any
    of the Debenture, it will not offer, sell, pledge or otherwise transfer any of such securities, directly or indirectly, unless
    the transfer is:

 

	 	 	(i)	to
    the Corporation, or a subsidiary thereof (though the Corporation or its subsidiaries are under no obligation to purchase any
    such Debenture);
	 	 	 	 
	 	 	(ii)	made
    outside the United States in accordance with Rule 904 of Regulation S and in compliance with applicable local laws and regulations;

 

    	 

    	21

    

 

	 	 	(iii)	made
    in compliance with the exemption from registration under the U.S. Securities Act provided by Rule 144 under the U.S. Securities
    Act, if available or Rule 144A under the U.S. Securities Act, if available;
	 	 	 	 
	 	 	(iv)	in
    another transaction that does not require registration under the U.S. Securities Act, and the holder of the Debenture has
    furnished to the Corporation an opinion of counsel of recognized standing in form and substance reasonably satisfactory to
    the Corporation to such effect; or
	 	 	 	 
	 	 	(v)	pursuant
    to an effective registration statement under the U.S. Securities Act, and in each case in compliance with any applicable state
    securities laws in the United States;

 

	 	(d)	Upon
    the original issuance of the Debenture and until such time as is no longer required under applicable requirements of the U.S.
    Securities Act or applicable state securities laws, all certificates representing the Debenture sold in the United States
    to Accredited Investors, and all certificates issued in exchange therefor or in substitution thereof, shall bear a legend
    substantially in the following form:

 

“THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED
(THE “U.S. SECURITIES ACT”) OR U.S. STATE SECURITIES LAWS. THESE SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED, DIRECTLY OR INDIRECTLY, ONLY (A) TO BRIACELL THERAPEUTICS CORP. (THE “CORPORATION”), (B) OUTSIDE THE
UNITED STATES IN COMPLIANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE LOCAL
LAWS AND REGULATIONS, (C) IN COMPLIANCE WITH THE EXEMPTION FROM THE REGISTRATION REQUIREMENTS UNDER THE U.S. SECURITIES ACT PROVIDED
BY (I) RULE 144 THEREUNDER IF AVAILABLE OR (II) RULE 144A THEREUNDER, IF AVAILABLE, AND IN EACH CASE IN ACCORDANCE WITH APPLICABLE
U.S. STATE SECURITIES LAWS, (D) IN ANOTHER TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY
APPLICABLE STATE SECURITIES LAWS, OR (E) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE U.S. SECURITIES ACT, PROVIDED
THAT, IN THE CASE OF TRANSFERS PURSUANT TO (C)(I) OR (D) ABOVE, THE HOLDER HAS, PRIOR TO SUCH TRANSFER, FURNISHED TO THE CORPORATION
AN OPINION OF COUNSEL OR OTHER EVIDENCE OF EXEMPTION, IN EITHER CASE REASONABLY SATISFACTORY TO THE CORPORATION. DELIVERY OF THIS
CERTIFICATE MAY NOT CONSTITUTE “GOOD DELIVERY” IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA.”

 

    	 

    	22

    

 

provided,
that if, the Debenture are being sold in compliance with the requirements of Rule 904 of Regulation S and in compliance with applicable
local laws and regulations, the above legend may be removed by providing a declaration to the Corporation and to the transfer
agent for the Corporation, in the form attached as Schedule “B” to this Subscription Agreement (or as the Corporation
may prescribe from time to time); provided further, if any of the Debenture are being sold pursuant to Rule 144 under the U.S.
Securities Act, if available, the legend may be removed by delivering to the Corporation and the transfer agent for the Corporation
an opinion of counsel of recognized standing in form and substance reasonably satisfactory to the Corporation, to the effect that
the legend is no longer required under applicable requirements of the U.S. Securities Act.

 

Notwithstanding
the foregoing, the transfer agent for the Corporation may impose additional requirements for the removal of legends from securities
sold in compliance with Rule 904 of Regulation S in the future;

 

	 	(e)	The
    Purchaser consents to the Corporation making a notation on its records or giving instructions to any transfer agent of the
    Debenture in order to implement the restrictions on transfer set forth and described herein;
	 	 	 
	 	(f)	If
    required by applicable securities legislation, regulatory policy or order or by any securities commission, stock exchange
    or other regulatory authority, the Purchaser will execute, deliver, file and otherwise assist the Corporation in filing reports,
    questionnaires, undertakings and other documents with respect to the ownership of the Debenture;
	 	 	 
	 	(g)	The
    Purchaser acknowledges that neither the Corporation nor any person representing the Corporation has made any representation
    to it with respect to the Corporation or the offering or sale of the Debenture, other than the information contained or incorporated
    by reference in this Subscription Agreement, which has been delivered to it and upon which it is relying in making its investment
    decision with respect to the Debenture;
	 	 	 
	 	(h)	The
    Purchaser understands that the Corporation is not obligated to file and has no present intention of filing with the U.S. Securities
    and Exchange Commission or with any state securities administrator any registration statement in respect of resales of the
    Debenture in the United States, and acknowledges that there are substantial restrictions on the transferability of the Debenture
    and that it may not be possible for the Purchaser to readily liquidate his, her or its investment in the case of an emergency
    at any time;
	 	 	 
	 	(i)	The
    Purchaser understands and agrees that the financial statements of the Corporation have been prepared in accordance with International
    Financial Reporting Standards, as issued by the International Accounting Standards Board, and are subject to Canadian auditing
    and auditor independence standards, which differ in some respects from United States generally accepted accounting principles,
    and United States auditing and auditor independence standards, respectively, and thus may not be comparable to financial statements
    of United States companies;
	 	 	 
	 	(j)	The
    Purchaser understands and agrees that there may be material tax consequences to it of an acquisition, holding, exercise or
    disposition of the Debenture. The Corporation gives no opinion and makes no representation with respect to the tax consequences
    to the Purchaser under United States, state, local or foreign tax law of its acquisition, holding, exercise or disposition
    of the Debenture, and the Purchaser acknowledges that it is solely responsible for determining the tax consequences to it
    with respect to its investment, including whether the Corporation will at any given time be deemed a “passive foreign
    investment company” within the meaning of Section 1297 of the United States Internal Revenue Code of 1986, as amended;
    

 

    	 

    	23

    

 

	 	(k)	The
    Purchaser is aware that its ability to enforce civil liabilities under the United States federal securities laws may be affected
    adversely by, among other things: (i) the fact that the Corporation is organized under the laws of Ontario, Canada; (ii) some
    or all of the directors and officers may be residents of countries other than the United States; and (iii) all or a substantial
    portion of the assets of the Corporation and such persons may be located outside the United States;
	 	 	 
	 	(l)	The
    office or other address of the Purchaser at which the Purchaser received and accepted the offer to purchase the Debenture
    is the address listed as the “Purchaser’s Residential Address” on the face page of the Subscription
    Agreement;
	 	 	 
	 	(m)	That
    the funds representing the Subscription Price which will be advanced by the Purchaser to the Corporation, hereunder will not
    represent proceeds of crime for the purposes of the Uniting and Strengthening America by Providing Appropriate Tools Required
    to Intercept and Obstruct Terrorism Act (the “PATRIOT Act”) and the Purchaser acknowledges that the
    Corporation may in the future be required by law to disclose the Purchaser’s name and other information relating to
    the subscription agreement and the Purchaser’s subscription hereunder, on a confidential basis, pursuant to the PATRIOT
    Act. No portion of the Aggregate Subscription Price to be provided by the Purchaser (i) has been or will be derived from or
    related to any activity that is deemed criminal under the laws of the United States, or any other jurisdiction, or (ii) is
    being tendered on behalf of a person or entity who has not been identified to or by the Purchaser, and it shall promptly notify
    the Corporation if the Purchaser discovers that any of such representations ceases to be true and provide the Corporation
    with appropriate information in connection therewith; and
	 	 	 
	 	(n)	The
    provisions of this United States Accredited Investor Representation Letter will be true and correct both as of the date of
    execution of this Subscription Agreement and as of the Closing Date.

 

The
Purchaser undertakes to notify the Corporation immediately of any change in any representation, warranty or other information
relating to the Purchaser or, if applicable, the beneficial purchaser set forth herein, which takes place prior to the Closing
Date.

 

	DATED
    at __________________________	this
    ___ day of _______________, 2020.
	 	 
	 	 
	Name
    of Entity	 
	 	 
	 	 
	Type
    of Entity	 
	 	 
	 	 
	Signature
    of Person Signing	 
	 	 
	 	 
	Print
    or Type Name and Title of Person Signing	 
	 	 

 

    	 

    	24

    

 

APPENDIX
1 TO SCHEDULE “A” 

FORM
OF U.S. ACCREDITED INVESTOR CERTIFICATE

 

In
connection with the purchase of a Debenture of BriaCell Therapeutics Corp. (the “Corporation”) by the undersigned,
as an integral part of the accompanying Subscription Agreement, the undersigned hereby represents and warrants to the Corporation
that the undersigned, and each beneficial purchaser, if any, on whose behalf the undersigned is subscribing for the Debenture,
satisfies one or more of the following accredited investor categories, within the meaning of Rule 501(a) of Regulation D under
the U.S. Securities Act (please write “PUR” for the undersigned Purchaser, and “BP” for each beneficial
purchaser, if any, on each line that applies):

 

	 	_______Category
    1.	A
    bank, as defined in Section 3(a)(2) of the U.S. Securities Act, whether acting in its individual or fiduciary capacity; a
    savings and loan association or other institution as defined in Section 3(a)(5)(A) of the U.S. Securities Act, whether acting
    in its individual or fiduciary capacity; a broker or dealer registered pursuant to Section 15 of the United States Securities
    Exchange Act of 1934, as amended; an insurance company as defined in Section 2(a)(13) of the U.S. Securities Act; an investment
    company registered under the United States Investment Company Act of 1940, as amended; a business development company as defined
    in Section 2(a)(48) of the United States Investment Company Act of 1940, as amended; a small business investment company licensed
    by the U.S. Small Business Administration under Section 301 (c) or (d) of the United States Small Business Investment Act
    of 1958, as amended; a plan established and maintained by a state, its political subdivisions or any agency or instrumentality
    of a state or its political subdivisions, for the benefit of its employees, with total assets in excess of US$5,000,000; or
    an employee benefit plan within the meaning of the United States Employee Retirement Income Security Act of 1974, as amended,
    in which the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such Act, which is either a bank,
    savings and loan association, insurance company or registered investment adviser, or an employee benefit plan with total assets
    in excess of US$5,000,000 or, if a self-directed plan, with investment decisions made solely by persons who are “accredited
    investors” (as such term is defined in Rule 501(a) of Regulation D under the U.S. Securities Act); or
	 	 	 
	 	_______
    Category 2.	A
    private business development company as defined in Section 202(a)(22) of the United States Investment Advisers Act of 1940,
    as amended; or
	 	 	 
	 	_______
    Category 3.	An
    organization described in Section 501(c)(3) of the United States Internal Revenue Code of 1986, as amended, a corporation,
    a Massachusetts or similar business trust, a limited liability company or a partnership, not formed for the specific purpose
    of acquiring the Debenture offered, with total assets in excess of US$5,000,000; or
	 	 	 
	 	_______
    Category 4.	A
    director or executive officer of the Corporation; or
	 	 	 
	 	_______
    Category 5.	A
    natural person with individual “net worth”, or joint “net worth” with his or her spouse, at the time
    of purchase in excess of US$1,000,000;

 

    	 

    	25

    

 

Note:
For purposes of calculating “net worth” under this paragraph:

 

(i)
The person’s primary residence shall not be included as an asset;

 

(ii)
Indebtedness that is secured by the person’s primary residence, up to the estimated fair market value of the primary residence
at the time of the sale of securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding
at the time of the sale of the Debenture exceeds the amount outstanding 60 days before such time, other than as a result of the
acquisition of the primary residence, the amount of such excess shall be included as a liability); and

 

(iii)
Indebtedness that is secured by the person’s primary residence in excess of the estimated fair market value of the primary
residence at the time of the sale of the Debenture shall be included as a liability; or

 

	 	_______
    Category 6.	A
    natural person who had an individual income in excess of US$200,000 in each of the last two years or joint income with his
    or her spouse in excess of US$300,000 in each of those years, and who reasonably expects to reach the same income level in
    the current year; or
	 	 	 
	 	_______
    Category 7.	A
    trust, with total assets in excess of US$5,000,000, not formed for the specific purpose of acquiring the Debenture, whose
    purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) under the U.S. Securities Act.
	 	 	 
	 	_______
    Category 8.	An
    entity in which all of the equity owners are Accredited Investors.

 

The
Purchaser acknowledges that if it is an individual U.S. Accredited Investor that is relying on the net worth or income eligibility
qualifications set forth in Category 5 or Category 6 above, such Purchaser shall also complete and deliver to the Corporation
a U.S. Individual Accredited Investor Questionnaire in the form attached as Appendix 2 to this Schedule “A”.

 

Terms
used herein but not otherwise defined have the meaning ascribed hereto in the accompanying Subscription Agreement.

 

	 	Dated:
    	____________________	 	Signed:
    	________________________________
	 	 	 	 
	 	 	 	 
	 	 	 	

        Print
        the Name of Purchaser

	 	 	 	 
	 	 	 	 
	 	 	 	

        Print
        Name and Title of Authorized Signing Officer

 

    	 

    	26

    

 

APPENDIX
2 TO SCHEDULE “A”

 

U.S.
INDIVIDUAL ACCREDITED INVESTOR QUESTIONNAIRE

 

I
understand that in order to be accepted as an “accredited investor”, I must satisfy certain of the following standards.
The undersigned hereby represents and warrants to BriaCell Therapeutics Corp. (the “Corporation”) as follows:

 

GENERAL
INFORMATION REQUIRED OF EACH PROSPECTIVE INVESTOR:

 

1.
General Information 

 

	Name(s):
    	_______________________	 	_______________________
	 	 	 	 
	Principal
    Residence: 	_______________________ 	 	_______________________
	 	 	 	 
	 	_______________________	 	_______________________
	 	 	 	 
	 	_______________________	 	_______________________
	 	 	 	 
	Business
    Hours Telephone:	 _______________________	 	_______________________
	 	 	 	 
	Home
    Telephone:	 _______________________	 	_______________________
	 	 	 	 
	Email:	_______________________	 	_______________________

 

2.
Financial Status. Please answer the following questions concerning your financial status by marking the appropriate box and
filling in the blanks.

 

2.1
Does your individual or joint (together with your spouse) net worth exceed US$1,000,000? For the purpose of calculating your
individual or joint (together with your spouse) net worth, (i) your primary residence shall not be included as an asset, (ii)
indebtedness that is secured by your primary residence, up to the estimated fair market value of the primary residence as of the
date hereof, shall not be included as a liability (except that if the amount of such indebtedness outstanding as of the date hereof
exceeds the amount outstanding 60 days before the date hereof, other than as a result of the acquisition of the primary residence,
the amount of such excess shall be included as a liability) and (iii) indebtedness that is secured by your primary residence in
excess of the estimated fair market value of your primary residence as of the date hereof shall be included as a liability:

 

	 	[  ] 	Yes
    	 	[  ]	No

 

2.1.1
If you answered “No” to Question 2.1, please indicate the actual amount of individual or joint (together with
your spouse) net worth (calculated in accordance with the instructions provided in Question 2.1 above).

 

US$
______________

 

2.2
Please indicate, for each of the two most recent years, what your individual income (or joint income together with your spouse)
was, and for the current year what your individual income (or joint income together with your spouse) is expected to be.

 

    	 

    	27

    

 

	 	2017
    Individual 	____________________	 	Joint	 ____________________
	 	 	 	 	 	 
	 	2018
    Individual 	____________________	 	Joint	 ____________________
	 	 	 	 	 	 
	 	2020
    Individual 	____________________	 	Joint	______________________

 

3.
Financial Background. Please respond to the following questions, supplying as much detail as possible in order to make your
answers complete.

 

3.1
Indicate by check mark which of the following categories best describes the extent of your prior experience in the areas of
investment listed below:

 

	No
    Experience	 	Some
    Experience	 	Substantial
    Experience
	 	 	 	 	 
	[  ]	 	[  ]	 	[  ]
    Marketable Securities
	 	 	 	 	 
	[  ]	 	[  ]	 	[  ]
Securities for which no public market exists

 

3.2
For those investments for which you indicated “Substantial Experience” or “Some Experience” in question
3.1 above, please answer the following additional question:

 

How
often do you make your own investment decisions with respect to such investments?

 

3.3
Do you have adequate means of providing for your current needs and personal contingencies and have no need for liquidity in
such investments?

 

	 	[  ] 	Yes
    	 	[  ]	No

 

4.
Prior Purchases of Securities. Have you made prior purchases of securities sold in reliance on the private offering exemption
from registration under the U.S. Securities Act:

 

	 	[  ] 	Yes
    	 	[  ]	No

 

I
hereby represent and warrant that:

 

(a)
I, individually or together with my spouse, have a net worth (i.e., a total assets in excess of total liabilities, as calculated
in accordance with the instructions provided in Question 2.1 above) of at least US$1,000,000; or

 

(b)
I, individually (without my spouse), have had an income of not less than US$200,000 (or, jointly with my spouse, US$300,000) during
each of the last two years, and reasonably expect that I will have an income of at least US$200,000 (or US$300,000, together with
my spouse) during the present year.

 

The
foregoing representations and warranties and all other information which I have provided to the Corporation concerning myself
and my financial condition are true and accurate as of the date hereof. If in any respect, such representations, warranties, or
information shall not be true and accurate, I will give written notice of such fact to the Corporation specifying which representations,
warranties or information are not true and accurate, and the reasons therefor.

 

I
understand that the information contained herein is being furnished by me in order for the Corporation to determine my suitability
as an “accredited investor”, may be accepted by the Corporation in light of the requirements of Regulation
D under the U.S. Securities Act and that the Corporation will rely on the information contained herein for purposes of such determination.

 

IN
WITNESS WHEREOF, the undersigned has executed this U.S. Individual Accredited Investor Questionnaire as of the________day of _______________________,
2020.

 

	 	 
	Print
    or Type Name	 
	 	 
	X
    ______________________________________________	 
	Signature	 

 

    	 

     

    

 

SCHEDULE
“B”`

 

FORM
OF DECLARATION FOR REMOVAL OF U.S. LEGEND

 

	TO:	BriaCell
    Therapeutics Corp. (and any transfer agent for BriaCell Therapeutics Corp.)

 

The
undersigned (a) acknowledges that the sale of _____________________ Debenture of BriaCell Therapeutics Corp. (the “Issuer”)
to which this declaration relates, represented by certificate number ______________, is being made in reliance on Rule 904 of
Regulation S under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and (b)
certifies that (1) it is not an “affiliate” (as defined in Rule 405 under the U.S. Securities Act) of the Issuer,
(2) the offer of such securities was not made to a person in the United States, and either (A) at the time the buy order was originated,
the buyer was outside the United States, or the seller and any person acting on its behalf reasonably believe that the buyer was
outside the United States, or (B) the transaction was executed on or through the facilities of the Canadian Securities Exchange
(or another designated offshore securities market) and neither the seller nor any person acting on its behalf knows that the transaction
has been prearranged with a buyer in the United States, (3) neither the seller nor any affiliate of the seller nor any person
acting on any of their behalf has engaged or will engage in any “directed selling efforts” in the United States in
connection with the offer and sale of such securities, (4) the sale is bona fide and not for the purpose of “washing off”
the resale restrictions imposed because the securities are “restricted securities” (as such term is defined in Rule
144(a)(3) under the U.S. Securities Act), (5) the seller does not intend to replace the securities sold in reliance on Rule 904
of Regulation S under the U.S. Securities Act with fungible unrestricted securities, and (6) the contemplated sale is not a transaction,
or part of a series of transactions which, although in technical compliance with Regulation S under the U.S. Securities Act, is
part of a plan or scheme to evade the registration provisions of the U.S. Securities Act. Terms used herein have the meanings
given to them by Regulation S under the U.S. Securities Act.

 

	Dated: ___________	 	 
	 	By:

        
	 
	 	Signature	 
	 	 
	 	Print
        name of Signatory

        (if
        different from Purchaser)

	 	 
	 	Title

 

    	 

     

    

 

SCHEDULE
C

NON-INDIVIDUAL SUBSCRIBERS

 

Complete
this Schedule C for non-individual Subscribers if the Subscriber, (i) is a member of the “Pro Group” (as described
below), or (ii) is (or will be after completion of the Offering) an “Insider” (as described below), or (iii) will
be a holder of more than 5% of the common shares of the Corporation after completion of the Offering and assuming conversion of
the Debenture and exercise of the Warrants.

 

	A	Registration
    Form
	 	 
	The
    Subscriber either [check appropriate box]:
	 
	[  ]	has
    previously filed with the TSX Venture Exchange (the “TSXV”) a Form 4C, Corporate Placee Registration Form,
    represents and warrants that there has been no change to any of the information in the Corporate Placee Registration Form
    previously filed with the TSXV up to the date hereof; or
	 	 
	[  ]	hereby
    delivers a completed Form 4C, Corporate Placee Registration Form, in the form attached as Appendix A to this Schedule C to
    the Corporation for filing with the TSXV.
	 	 
	B.	Insider
    Status
	 	 
	The
    Subscriber either [check appropriate box]:
	 
	[  ]	is
    an “Insider” of the Corporation as defined in the policies of the TSXV as follows:
	 	 
	 	(a)	a
    director or senior officer of the Corporation;
	 	 	 
	 	(b)	a
    director or senior officer of a company that is itself an Insider or subsidiary of the Corporation;
	 	 	 
	 	(c)	a
    person that beneficially owns or controls, directly or indirectly, voting shares of the Corporation carrying more than 10%
    of the voting rights attached to all the Corporation’s outstanding voting shares; or
	 	 	 
	 	(d)	the
    Corporation itself if it holds any of its own securities; or
	 	 	 
	[  ]	is
    not an Insider of the Corporation.

 

    	 

     

    

 

	C.	Member
    of “Pro Group”
	 	 
	The
    Subscriber either [check appropriate box]:
	 
	[  ]	is
    a member of the “Pro Group” as defined in the Rules of the TSXV, as follows:

 

	 	1	subject
    to subparagraphs (2), (3) and (4), either individually or as a group:

 

	 	(a)	the
    member (i.e. a member of the TSXV under TSXV requirements);
	 	 	 
	 	(b)	employees
    of the member;
	 	 	 
	 	(c)	partners,
    officers or directors of the member;
	 	 	 
	 	(d)	affiliates
    of the member; and
	 	 	 
	 	(e)	associates
    of any parties referred to in subparagraphs (a) through (d);

 

	 	2.	the
    TSXV may, in its discretion, include a person or party in the Pro Group for the purposes of a particular calculation where
    the TSXV determines that the person is not acting at arm’s length with the member;
	 	 	 
	 	3.	the
    TSXV may, in its discretion, exclude a person from the Pro Group for the purposes of a particular calculation where the TSXV
    determines that the person is acting at arm’s length with the member;
	 	 	 
	 	4.	the
        member may deem a person who would otherwise be included in the Pro Group pursuant to subparagraph (1) to be excluded
        from the Pro Group where the member determines that:

         

 

	 	(a)	the
    person is an affiliate or associate of the member acting at arm’s length of the member;
	 	 	 
	 	(b)	the
    associate or affiliate has a separate corporate and reporting structure;
	 	 	 
	 	(c)	there
    are sufficient controls on information flowing between the member and the associate or affiliate; and
	 	 	 
	 	(d)	the
    member maintains a list of such excluded persons; or

 

	[  ]	is
    not a member of the Pro Group.

 

    	 

     

    

 

appendix
a to schedule C

 

 

 

TSX VENTURE EXCHANGE

PRIVATE PLACEMENT FORM

 

FORM
4C

CORPORATE PLACEE REGISTRATION FORM

 

This
Form will remain on file with the Exchange and must be completed if required under section 4(b) of Part II of Form 4B. The corporation,
trust, portfolio manager or other entity (the “Placee”) need only file it on one time basis, and it will be
referenced for all subsequent Private Placements in which it participates. If any of the information provided in this Form changes,
the Placee must notify the Exchange prior to participating in further placements with Exchange listed Issuers. If as a result
of the Private Placement, the Placee becomes an Insider of the Corporation, Insiders of the Placee are reminded that they must
file a Personal Information Form (2A) or, if applicable, Declarations, with the Exchange.

 

	1.	Placee
    Information:

 

	 	(a)	Name:
______________________________________________________________________    
	 	 	 
	 	(b)	Complete
    Address: ____________________________________________________________
	 	 	 
	 	(c)	Jurisdiction
    of Incorporation or Creation: ____________________________________________

 

	2.	(a)	Is
    the Placee purchasing securities as a portfolio manager: (Yes/No)? _______________________

 

	 	(b)	Is
        the Placee carrying on business as a portfolio manager outside of Canada:

        (Yes/No)?____________________________________________________________________

 

	3.	If
    the answer to 2(b) above was “Yes”, the undersigned certifies that:

 

	 	(a)	it
    is purchasing securities of the Corporation on behalf of managed accounts for which it is making the investment decision to
    purchase the securities and has full discretion to purchase or sell securities for such accounts without requiring the client’s
    express consent to a transaction;
	 	 	 
	 	(b)	it
    carries on the business of managing the investment portfolios of clients through discretionary authority granted by those
    clients (a “portfolio manager” business) in ____________________ [jurisdiction], and it is permitted by law to
    carry on a portfolio manager business in that jurisdiction;
	 	 	 
	 	(c)	it
    was not created solely or primarily for the purpose of purchasing securities of the Corporation;
	 	 	 
	 	(d)	the
    total asset value of the investment portfolios it manages on behalf of clients is not less than $20,000,000; and
	 	 	 
	 	(e)	it
    has no reasonable grounds to believe, that any of the directors, senior officers and other insiders of the Corporation, and
    the persons that carry on investor relations activities for the Corporation has a beneficial interest in any of the managed
    accounts for which it is purchasing.

 

    	 

     

    

 

	4.	If
    the answer to 2(a). above was “No”, please provide the names and addresses of Control Persons of the Placee:

 

	Name
    *	 	City	 	Province
    or State	 	Country
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 

 

*
If the Control Person is not an individual, provide the name of the individual that makes the investment decisions on behalf of
the Control Person.

 

	5.	Acknowledgement
                                         - Personal Information and Securities Laws

 

		(a)	“Personal
                                         Information” means any information about an identifiable individual, and includes
                                         information contained in sections 1, 2 and 4, as applicable, of this Form.

 

The
undersigned hereby acknowledges and agrees that it has obtained the express written consent of each individual to:

 

		(i)	the
                                         disclosure of Personal Information by the undersigned to the Exchange (as defined in
                                         Appendix 6B) pursuant to this Form; and

 

		(ii)	the
                                         collection, use and disclosure of Personal Information by the Exchange for the purposes
                                         described in Appendix 6B or as otherwise identified by the Exchange, from time to time.

 

		(b)	The
                                         undersigned acknowledges that it is bound by the provisions of applicable Securities
                                         Law, including provisions concerning the filing of insider reports and reports of acquisitions.

 

Dated
and certified (if applicable), acknowledged and agreed, at _____________________________________________on ____________________________________.

 

	 	 
	 	(Name
    of Purchaser - please print)
	 	 
	 	 
	 	(Authorized
    Signature)
	 	 
	 	 
	 	(Official
    Capacity - please print)
	 	 
	 	 
	 	(Please
    print name of individual whose signature
	 	appears
    above)

 

THIS
IS NOT A PUBLIC DOCUMENT

 

    	 

     

    

 

SCHEDULE
D

 

TERM
SHEET

 

(See
attached)

 

    	 

     

    

 

SCHEDULE
E

 

DEBENTURE
CERTIFICATE

 

(See
attached)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]